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Inhibitors
Abstract
The first part (Chapter 1 and 2) of this dissertation presents a novel combination study of melanoma
therapy. Acquired clinical resistance to vemurafenib, a selective BRAFV600E inhibitor, arises frequently
after short term chemotherapy. Since the inhibitions of targets in the RAFMEK-ERK pathway result in G0/
G1 cell cycle arrest, vemurafenib-resistant cancer cells are expected to escape this cell cycle arrest and
progress to subsequent G2/M phase. We hypothesized that a combined therapy using vemurafenib with a
G2/M phase blocking agent will trap resistant cells and overcome vemurafenib resistance. To test this
hypothesis, we first determined the combination index (CI) values of our novel tubulin inhibitor ABI-274
and vemurafenib on parental human A375 and MDA-MB-435 melanoma cell lines to be 0.32 and 0.1,
respectively, suggesting strong synergy for the combination. We then developed an A375RF21 subline
with significant acquired resistance to vemurafenib and confirmed the strong synergistic effect. Next we
studied the potential mechanisms of overcoming vemurafenib resistance. Flow cytometry confirmed that
the combination of ABI-274 and vemurafenib synergistically arrested cells in G1/G2/M phase, and
significantly increased apoptosis in both parental A375 and the vemurafenib-resistant A375RF21 cells.
Western blot analysis revealed that the combination treatment effectively reduced the level of
phosphorylated and total AKT, activated the apoptosis cascade, and increased cleaved caspase-3 and
cleaved PARP, but had no significant influence on the level of ERK phosphorylation. Finally, in vivo coadministration of vemurafenib with ABI-274 showed strong synergistic efficacy in the vemurafenibresistant xenograft model in nude mice. Overall, these results offer a rational combination strategy to
significantly enhance the therapeutic benefit in melanoma patients who inevitably become resistant to
current BRAF inhibition therapy.
The second part (Chapter 3 to 5) of this dissertation focuses on the discovery of a series of small
molecule survivin inhibitors. Inhibitors of apoptosis (IAP) proteins are widely considered as promising
cancer drug targets, especially for drug-resistant tumors. Mimicking the IAP-binding motif of second
mitochondria-derived activator of caspases (Smac) is a rational strategy to design potential IAP
inhibitors. In this report, we used the bioactive conformation of AVPI tetrapeptide in the N-terminus of
Smac as a template and performed a shape-based virtual screening against a drug-like compound library
to identify novel IAP inhibitors. Top hits were subsequently docked to available IAP crystal structures as a
secondary screening followed by validation using in vitro biological assays. Four novel hit compounds
were identified that potently inhibited cell growth in two human melanoma (A375 and M14) and two
human prostate (PC-3 and DU145) cancer cell lines. The best compound, UC-112, has IC50 values ranging
from 0.7 to 3.4 µM. UC-112 also potently inhibits the growth of P-glycoprotein (Pgp) overexpressed
multidrug-resistant cancer cells, strongly activates capase-3/7 and caspase-9 activities, and selectively
down-regulates survivin level at a concentration as low as 1 µM. Co-incubation of UC-112 with a known
proteasome inhibitor (MG132) rescued survivin inhibition, consistent with the anticipated mechanism of
action for UC-112. As a single agent, UC-112 strongly inhibits tumor growth and reduces both XIAP and
survivin levels in an A375 human melanoma xenograft model in vivo. Three analogs generated from
UC-112 structural modification along with template compound UC-112 were submitted to NCI-60 cancer
cell line screening. The results indicated that structural modification of UC-112 to give our best compound
MX106 has improved activity by four fold (2.2 µM for UC-112 vs. 0.5 µM for MX106, average GI50 values
over all cancer cell lines in the NCI-60 panel).Western blot analyses demonstrated the new compounds
maintained high selectivity for survivin inhibition over other members in the inhibitiors of apoptosis
protein family. When tested in an A375 human melanoma xenograft model, the most active compound
MX106 effectively suppressed tumor growth and strongly induced cancer cell apoptosis in tumor tissues.

Taken together, this novel scaffold is promising for the development of selective survivin inhibitors as
potential anticancer agents.
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ABSTRACT
The first part (Chapter 1 and 2) of this dissertation presents a novel combination
study of melanoma therapy. Acquired clinical resistance to vemurafenib, a selective
BRAFV600E inhibitor, arises frequently after short term chemotherapy. Since the
inhibitions of targets in the RAF-MEK-ERK pathway result in G0/G1 cell cycle arrest,
vemurafenib-resistant cancer cells are expected to escape this cell cycle arrest and
progress to subsequent G2/M phase. We hypothesized that a combined therapy using
vemurafenib with a G2/M phase blocking agent will trap resistant cells and overcome
vemurafenib resistance. To test this hypothesis, we first determined the combination
index (CI) values of our novel tubulin inhibitor ABI-274 and vemurafenib on parental
human A375 and MDA-MB-435 melanoma cell lines to be 0.32 and 0.1, respectively,
suggesting strong synergy for the combination. We then developed an A375RF21 subline
with significant acquired resistance to vemurafenib and confirmed the strong synergistic
effect. Next we studied the potential mechanisms of overcoming vemurafenib resistance.
Flow cytometry confirmed that the combination of ABI-274 and vemurafenib
synergistically arrested cells in G1/G2/M phase, and significantly increased apoptosis in
both parental A375 and the vemurafenib-resistant A375RF21 cells. Western blot analysis
revealed that the combination treatment effectively reduced the level of phosphorylated
and total AKT, activated the apoptosis cascade, and increased cleaved caspase-3 and
cleaved PARP, but had no significant influence on the level of ERK phosphorylation.
Finally, in vivo co-administration of vemurafenib with ABI-274 showed strong
synergistic efficacy in the vemurafenib-resistant xenograft model in nude mice. Overall,
these results offer a rational combination strategy to significantly enhance the therapeutic
benefit in melanoma patients who inevitably become resistant to current BRAF inhibition
therapy.
The second part (Chapter 3 to 5) of this dissertation focuses on the discovery of a
series of small molecule survivin inhibitors. Inhibitors of apoptosis (IAP) proteins are
widely considered as promising cancer drug targets, especially for drug-resistant tumors.
Mimicking the IAP-binding motif of second mitochondria-derived activator of caspases
(Smac) is a rational strategy to design potential IAP inhibitors. In this report, we used the
bioactive conformation of AVPI tetrapeptide in the N-terminus of Smac as a template and
performed a shape-based virtual screening against a drug-like compound library to
identify novel IAP inhibitors. Top hits were subsequently docked to available IAP crystal
structures as a secondary screening followed by validation using in vitro biological
assays. Four novel hit compounds were identified that potently inhibited cell growth in
two human melanoma (A375 and M14) and two human prostate (PC-3 and DU145)
cancer cell lines. The best compound, UC-112, has IC50 values ranging from 0.7 to 3.4
μM. UC-112 also potently inhibits the growth of P-glycoprotein (Pgp) overexpressed
multidrug-resistant cancer cells, strongly activates capase-3/7 and caspase-9 activities,
and selectively down-regulates survivin level at a concentration as low as 1 μM. Coincubation of UC-112 with a known proteasome inhibitor (MG132) rescued survivin
inhibition, consistent with the anticipated mechanism of action for UC-112. As a single
agent, UC-112 strongly inhibits tumor growth and reduces both XIAP and survivin levels
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in an A375 human melanoma xenograft model in vivo. Three analogs generated from
UC-112 structural modification along with template compound UC-112 were submitted
to NCI-60 cancer cell line screening. The results indicated that structural modification of
UC-112 to give our best compound MX106 has improved activity by four fold (2.2 μM
for UC-112 vs. 0.5 μM for MX106, average GI50 values over all cancer cell lines in the
NCI-60 panel).Western blot analyses demonstrated the new compounds maintained high
selectivity for survivin inhibition over other members in the inhibitiors of apoptosis
protein family. When tested in an A375 human melanoma xenograft model, the most
active compound MX106 effectively suppressed tumor growth and strongly induced
cancer cell apoptosis in tumor tissues. Taken together, this novel scaffold is promising for
the development of selective survivin inhibitors as potential anticancer agents.

v

TABLE OF CONTENTS
CHAPTER 1. EMERGING DRUG COMBINATION APPROACHES IN
MELANOMA THERAPY ................................................................................................1
1.1 Introduction ................................................................................................................1
1.2 Combination of Kinase Inhibitors for Melanoma Treatment ....................................1
1.2.1 Combined Inhibitions Targeting Components within the Mitogenactivated Protein Kinase (MAPK) Signaling Pathway .....................................1
1.2.2 Combination Targeted Therapy Using Phosphatidylinositol 3-kinase
(PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Inhibitors ...............7
1.2.3 Combining Targeted Therapy with Anti-angiogenic Agents ............................8
1.2.4 Combination Therapy Using Targeted Therapy with Versatile
Chemotherapy Agents ......................................................................................9
1.3 Combinations Involving Immunotherapy in Melanoma Treatment ........................10
1.3.1 Combined Blockade of Immuno-checkpoints ................................................10
1.3.2 Combined Therapy Inhibiting both Immuno-checkpoint and MAPK
Signaling Pathway ..........................................................................................11
1.4 Conclusion ...............................................................................................................12
CHAPTER 2. OVERCOMING ACQUIRED RESISTANCE TO BRAF
INHIBITORS BY NOVEL SYNERGISTIC DRUG COMBINATION .....................14
2.1 Introduction ..............................................................................................................14
2.2 Materials and Methods.............................................................................................15
2.2.1 Reagents and Cell Lines ..................................................................................15
2.2.2 Cell Proliferation and In Vitro Combination Assay ........................................15
2.2.3 Cell Cycle Analysis .........................................................................................16
2.2.4 Tubulin Polymerization Assay ........................................................................16
2.2.5 Western Blot Analysis ....................................................................................16
2.2.6 Apoptosis Detection ........................................................................................16
2.2.7 Vemurafenib-resistant Tumor Xenograft and Treatment................................17
2.2.8 Pathology and Immunohistochemistry (IHC) Analysis ..................................17
2.2.9 Statistical Analysis ..........................................................................................18
2.3 Results ......................................................................................................................18
2.3.1 Combination of Vemurafenib with ABI Compound Showed Strong
Synergies in Parental BRAFV600E Mutant Melanoma Cell Lines ...................18
2.3.2 Combination of ABI-231 and Vemurafenib Produced Synergistic Cell
Cycle Arrests in Vemurafenib-sensitive A375 Cells ......................................18
2.3.3 Combination of ABI-231 and Vemurafenib Affected Related Protein
Levels in Vemurafenib-sensitive A375 Cells .................................................18
2.3.4 Establishment of Vemurafenib-resistant A375RF21 Melanoma Subline .......22
2.3.5 Combination of Vemurafenib with ABI-274 Showed Strong Synergies in
Vemurafenib-resistant A375RF21 Melanoma Cell Lines ..............................22
2.3.6 Combination of ABI-274 and Vemurafenib Produced Synergistic Cell
Cycle Arrests in A375RF21 Cells ..................................................................26

vi

2.3.7 Combination Treatment Induced Significantly Increased Apoptotic and
Cell Death in Vemurafenib-resistant Cells .....................................................26
2.3.8 Combination Mitigates Acquired Vemurafenib Resistance by Downregulating pAKT or Total AKT and Activating Apoptosis Cascades ............30
2.3.9 Combination of Vemurafenib and ABI-274 Synergistically Suppresses
Vemurafenib-resistant Tumor Growth In Vivo ...............................................34
2.3.10 Establishment of Vemurafenib-resistant MDA-MB-435 VemR Melanoma
Subline ............................................................................................................38
2.3.11 Combination of Tubulin Inhibitor with BRAF Inhibitor Showed
Synergistic Anti-proliferation Effects in Expanded Panel of Vemurafenib
or Trametinib Resistant Cell Lines .................................................................41
2.4 Discussion ................................................................................................................41
CHAPTER 3. LITERATURE REVIEW OF SURVIVIN AND ITS
ANTAGONISTS ..............................................................................................................45
3.1 The Structure and Tissue Distribution of Survivin ..................................................45
3.2 The Expression and Regulation of Survivin ............................................................45
3.2.1 Control of Survivin Gene Expression by Transcription Factors .....................47
3.2.2 Post-translational Modification of Survivin....................................................47
3.3 The Nodal Functions of Survivin.............................................................................48
3.3.1 Apoptosis ........................................................................................................48
3.3.2 Mitotic .............................................................................................................49
3.3.3 DNA Repair and Autophagy ...........................................................................49
3.4 Current Antagonists of Survivin as Anti-tumor Agents ..........................................49
3.4.1 Small Molecule Inhibitors...............................................................................49
3.4.2 Survivin Antisense Oligonucleotides (ASOs) ................................................50
3.4.3 Dominant Negative Survivin (DNS) ...............................................................51
3.5 Conclusion ...............................................................................................................52
CHAPTER 4. DISCOVERY OF NOVEL SMAC MIMETIC AS SELECTIVE
SURVIVIN INHIBITOR .................................................................................................53
4.1 Introduction ..............................................................................................................53
4.2 Methods ...................................................................................................................54
4.2.1 Shape-based Virtual Screening .......................................................................54
4.2.2 Molecule Docking ...........................................................................................54
4.2.3 Cell Culture and Reagents ..............................................................................54
4.2.4 Cell Viability Assay ........................................................................................55
4.2.5 siRNA Silencing Survivin or XIAP Expression .............................................55
4.2.6 Caspase Functional Assay...............................................................................55
4.2.7 Western Blotting .............................................................................................55
4.2.8 Flow Cytometry Analysis ...............................................................................56
4.2.9 Human Melanoma A375 Tumor Xenograft Model and Treatment ................56
4.2.10 Pathology Analysis .........................................................................................57
4.2.11 TUNEL Assay .................................................................................................57
4.2.12 Statistical Analysis ..........................................................................................57
4.3 Results and Discussion ............................................................................................57

vii

4.3.1 Identification of Initial Hits from Virtual Screening ......................................57
4.3.2 Validation of Virtual Screening Using In Vitro Anti-proliferation Assay ......58
4.3.3 Hit Compounds Increased Caspase Activities Significantly Better than
Embelin ...........................................................................................................63
4.3.4 Western Blotting Analyses of IAPs Level Change in Cancer Cells ...............63
4.3.5 Proteasome Inhibitor MG132 Rescued the Down-regulated Survivin
Levels in Cancer Cells Treated by UC-112 ....................................................70
4.3.6 UC-112 Arrested A375 Melanoma Cells in G1 Phase ....................................70
4.3.7 UC-112 Inhibited Tumor Growth in a Melanoma Xenograft Model In
Vivo .................................................................................................................73
CHAPTER 5. ANTI-CANCER EFFICACY, PHYSIO-CHEMICAL
PROPERTY AND TARGET VALIDATION STUDIES OF OPTIMIZED UC112 ANALOGS .................................................................................................................76
5.1 Introduction ..............................................................................................................76
5.2 Materials and Methods.............................................................................................76
5.2.1 Cell Culture and Cell Viability Assay ............................................................76
5.2.2 NCI-60 Screening ...........................................................................................76
5.2.3 Western Blotting .............................................................................................77
5.2.4 DARTS Assay .................................................................................................77
5.2.5 Molecular Modeling........................................................................................77
5.2.6 Liver Microsomal Stability Study ...................................................................78
5.2.7 Plasma Protein Bounding Study .....................................................................78
5.2.8 In Vivo Anti-tumor Efficacy Test....................................................................78
5.2.9 TUNEL Assay .................................................................................................78
5.3 Results and Discussion ............................................................................................79
5.3.1 UC-112 Analogs Could Overcome Multidrug Resistance..............................79
5.3.2 UC-112 Analogs Showed Good Anti-proliferation Effects with Selectivity
in NCI-60 Cell Line Screening .......................................................................79
5.3.3 Mechanism of Action Studies .........................................................................82
5.3.4 Molecular Modeling Study .............................................................................82
5.3.5 In Vivo Anti-tumor Efficacy Assessment........................................................86
CHAPTER 6. SUMMARY AND FUTURE DIRECTION ..........................................89
LIST OF REFERENCES ................................................................................................91
VITA................................................................................................................................111

viii

LIST OF TABLES
Table 2-1.

Combination of vemurafenib with tubulin inhibitors showed synergistic
effect in the parental BRAFV600E melanoma cell lines as indicated by CI
values determined at ED50 ............................................................................19

Table 2-2.

Combination of vemurafenib with tubulin inhibitors showed synergistic
effect in the vemurafenib-resistant A375RF21 melanoma cell lines ...........25

Table 2-3.

Tumor growth inhibition (TGI) and tumor weight comparison for in vivo
combination of vemurafenib and ABI-274 in the resistant A375RF21
xenograft model (n = 7) ................................................................................37

Table 2-4.

Tumor growth inhibition (TGI) and tumor weight comparison for in vivo
combination of vemurafenib (30 mg/kg) and ABI-274 (15 mg/kg) in the
resistant A375RF21 xenograft model (n = 5)...............................................40

Table 2-5.

Combination of BRAF inhibitors with ABI-274 showed synergistic
effect in the expanded panel of vemurafenib-resistant melanoma cell
lines ..............................................................................................................43

Table 4-1.

Growth inhibitory percentages of UC compounds at a concentration of 3
μM or 10 μM (MTS assay, n = 4) and IC50 (μM) values of UC
compounds in comparison with embelin against cancer cell proliferation
(SRB assay, n = 4) ........................................................................................62

Table 4-2.

IC50 (μM) values of UC compounds in comparison with embelin against
normal cells proliferation (SRB assay, n = 4) ..............................................64

Table 4-3.

UC-112 overcomes Pgp-mediated drug resistance much better than
YM155 (n = 4)..............................................................................................71

Table 5-1.

In vitro anti-proliferation activities of UC-112 analogs determined by
MTS assay (n = 4) ........................................................................................80

ix

LIST OF FIGURES
Figure 1-1. The mechanisms of BRAF inhibitor vemurafenib (Vem) action, toxicity
and the interaction between melanoma cells with T lymphocytes .................3
Figure 1-2. The mechanisms of acquired resistance to BRAF inhibition..........................4
Figure 2-1. Cell cycle analysis of A375 cells incubated with single or combination
treatment for 24 h (n = 3) .............................................................................20
Figure 2-2. Representative images of western blotting results for A375 cell
incubated with either single or combination treatment for 24 h ..................21
Figure 2-3. Establishment of vemurafenib-resistant A375 melanoma cell line
A375RF21 from its parental A375 cell line using chronic selection over
3 months with increasing concentrations of vemurafenib ............................23
Figure 2-4. Major vemurafenib resistance mechanisms in A375RF21 cells are the
over-expression of PDGFRβ and the activations of the PI3K-AKT
pathway ........................................................................................................24
Figure 2-5. In vitro dose-response curves (n = 5) of each combination in A375 and
A375RF21 cells ............................................................................................27
Figure 2-6. Cell cycle analysis for combination of ABI-274 with vemurafenib (n =
4)...................................................................................................................28
Figure 2-7. Anti-phospho-histone H3 and PI (propidium iodide) bivariate staining
cell cycle analysis on vemurafenib-resistant A375RF21 cells .....................29
Figure 2-8. Combination of tubulin inhibitors with vemurafenib synergistically
increased proportion of cell apoptosis or death in resistant A375RF21
cells...............................................................................................................31
Figure 2-9. Effect of single agent and combination treatment on purified-protein
based tubulin polymerization assay (n = 3) ..................................................32
Figure 2-10. Western blot analysis with indicated antibodies on lysate of A375RF21
(A), MDA-MB-435 and WM164 cells (B) after 48h treatment while
GAPDH was used as a loading control ........................................................33
Figure 2-11. Western blotting analysis for cell lysates of A375RF21 incubated with
indicated treatment for 24 h .........................................................................35
Figure 2-12. In vivo combination of vemurafenib and ABI-274 in the resistant
A375RF21 xenograft model (n = 7) .............................................................36

x

Figure 2-13. In vivo combination of high dose vemurafenib (30 mg/kg) and ABI-274
(15 mg/kg) in the A375RF21 xenograft model (n = 5) ................................39
Figure 2-14. Establishment of BRAF inhibitor resistant MDA-MB-435 VemR subline
with chronically selection in vitro ................................................................42
Figure 3-1. The nodal functions of survivin and targets of survivin inhibitors. ..............46
Figure 4-1. In silico similarity alignments of template ligand, Smac N-terminus
tetrapeptide AVPI (blue stick), with representative UC compounds (UC222 in brown tube; UC-112 in yellow tube ..................................................59
Figure 4-2. In silico predicted binding poses of 50 hits selected for in vitro activity
evaluation docked into AVPI binding sides in different XIAP BIR3Smac complexes ...........................................................................................60
Figure 4-3. Cell growth inhibition percentages of XIAP inhibitor hits on human
melanoma A375 and M14 cells at 4 μM or 10 μM after 48 h incubation
determined by MTS assay (n =4) .................................................................61
Figure 4-4. Relative in vitro caspase activity of human melanoma A375 or human
prostate cancer PC-3 cells after treatment with UC compounds or
embelin at different concentrations (n = 4) ..................................................65
Figure 4-5. Compounds UC-112 and UC-222 down-regulate the IAP levels in vitro ....66
Figure 4-6. Lane density quantification data of western blotting analysis results
(A375 cells) in (A) Figure 4-5A and (B) Figure 4-5C .................................68
Figure 4-7. IC50 values of UC-112 increased in survivin or XIAP gene silenced
A375 and PC-3 cells .....................................................................................69
Figure 4-8. Proteasome inhibitor MG132 can rescue survivin inhibition by UC-112 ....72
Figure 4-9. UC-112 (20 mg/kg and 40 mg/kg) strongly suppress melanoma tumor
growth in an A375 xenograft mouse model (n = 7, i.p. injection 5 days
per week) ......................................................................................................74
Figure 4-10. Tumor images of in vivo anti-tumor efficacy evaluation of UC-112 (20
mg/kg and 40 mg/kg) on A375 xenograft nude mice model (n = 7, i.p.
injection five days per week for three continuous weeks) ...........................75
Figure 5-1. Average GI50 data for UC-112, compound MX35, MX86 and MX106
tested in NCI-60 anti-proliferative screening ...............................................81
Figure 5-2. Heat map showing the GI50 values (nM) for UC-112 and three analogs in
the NCI-60 screening ...................................................................................83

xi

Figure 5-3. Western blotting analysis of MX106 in A375 and PC-3 cell lines ...............84
Figure 5-4. Representative DARTS results for pronase-digested A375 or M14 cell
lysates ...........................................................................................................85
Figure 5-5. Potential binding pose of UC-112 and compound MX106 in the Smac
N-terminus tetra-peptide AVPI binding site of survivin crystal structure
(PDB entry: 3UIH) . .....................................................................................87
Figure 5-6. In vivo anti-tumor efficacy of compound MX106. .......................................88

xii

LIST OF ABBREVIATIONS
ABCG2
AICAR
AIF
ALL
AMPK
BCRP
BIR
BRAFi
CBP
CDK4
CDK6
CPC
CRPC
CSCC
CTL
CTLA-4
DNMT
EGF
EIASD
ER
FBS
FOXO3
H&E
HDAC6
HGF
HSP90
i.p.
IGF-1
IGF-1R
INCENP
JNK
LRP
MEKi
MRP
MTD
mTOR
MTPA
NF-κB
PD-1
PDGFRβ
PFS
Pgp
PI3K

ATP-binding cassette sub-family G member 2
5-aminoimidazole-4-carboxamide-1-b-D-ribofuranoside
apoptosis-inducing-factor
acute lymphoblastic leukemia
AMP-activated protein kinase
breast cancer resistant protein
baculoviral IAP repeat
BRAF inhibitors
CREB binding protein
cyclin-dependent kinase 4
cyclin-dependent kinase 6
chromosomal passenger complex
castration-resistant prostate cancer
cutaneous squamous cell carcinoma
cytotoxic T-lymphocyte
cytotoxic T lymphocyte-associated antigen 4
DNA methyl-transferase
epidermal growth factor
enzyme-inducing antiseizure drug
endoplasmic reticulum
fetal bovine serum
Forkhead box O3
hematoxylin and eosin
histone deacetylase 6
hepatocyte growth factor
heat shock protein 9
intraperitoneally
insulin-like growth factor 1
insulin-like growth factor 1 receptor
inner centromere protein
c-Jun N-terminal kinase
lung-resistance-associated protein
MEK1/MEK2 inhibitor
multidrug resistance-associated protein
maximum tolerable dose
mammalian target of rapamycin
microtubule-targeted tubulin-polymerizing agents
nuclear factors kappa-light-chain-enhancer of activated B cell
programmed cell death protein 1
platelet-derived growth factor receptor beta
progression-free survival
P-glycoprotein
phosphatidylinositol 3-kinase

xiii

PKA
PKC
PLK
PTEN
RLU
ROS
RTKs
SD
Smac
Sp1
SSC
STAT3
TGI
TNF-α
TTP
TUNEL
Vem
XAF
XIAP

protein kinase A
protein kinase C
polo-like kinase 1
phosphatase tensin
relative luminescence unit
reactive oxygen species
receptor tyrosine kinases
standard derivation
second mitochondria-derived activator of caspases
specificity protein 1
saline-sodium citrate
signal transducer and activator of transcription-3
tumor growth inhibition
tumor necrosis factor α
time to progression
terminal deoxynucleotidyltranferase (TdT)-mediated dUTP nick
end labeling
vemurafenib
XIAP–associated factor 1
X-linked inhibitor of apoptosis

xiv

CHAPTER 1.

EMERGING DRUG COMBINATION APPROACHES IN
MELANOMA THERAPY*
1.1 Introduction

The FDA approvals of ipilimumab targeting the cytotoxic T lymphocyteassociated antigen 4 (CTLA-4), pembrolizumab targeting the programmed cell death
protein 1 (PD-1), BRAF inhibitors vemurafenib and dabrafenib, and MEK inhibitor
trametinib represent significant milestones in more effective treatment of advanced
melanoma. However, it is clear that the use of these single-agent therapies have limitation
clinically. For example, ipilimumab only showed 4.5% objective response rate when used
alone in a Phase II clinical trial (1). The efficacy of vemurafenib lasts only 6.7 months
before the disease relapses especially in patients with metastatic melanoma (2).
Therefore, rational combination approaches are strongly preferred in order to improve the
overall patient progression-free survival (PFS), overcome or delay the development of
multi-drug resistance and reduce the incidents of side effects (3-6).
In this chapter, we will summarize the emerging combination therapy approaches
from both clinical trial and preclinical research in the past five years (7).
1.2 Combination of Kinase Inhibitors for Melanoma Treatment
1.2.1 Combined Inhibitions Targeting Components within the Mitogen-activated
Protein Kinase (MAPK) Signaling Pathway
1.2.1.1 Targeting BRAF: mechanism of action, toxicity and drug resistance
BRAF is a serine/threonine growth signal transduction protein kinase from RAF
family which plays important roles in the RAS/RAF/MEK/ERK pathway and directs cell
division, proliferation and secretion (8). BRAF inhibitors (BRAFi) are ATP-competitive
ligands which inactivate the function of BRAF protein by either stabilizing the inactive
form of kinase domain (sorafenib) or preferentially inhibit the active form of the kinase
(vemurafenib, dabrafenib) (9, 10). Various mutations of BRAF gene have been identified
in cancers including melanoma, colorectal and ovarian cancer. Around 60% of human
melanoma adopted the T1799A transversion in exon 15, which lead to BRAFV600E
mutation and the over-activated monomer phosphorylation for BRAFV600E (10, 11). The

* Reprinted with permission. Wang J, Miller DD and Li W. Emerging Drug Combination
Approaches in Melanoma Therapy, Melanoma - Current Clinical Management and
Future Therapeutics, Prof. Mandi Murph (Ed.), 2015. ISBN: 978-953-51-2036-0, InTech,
DOI: 10.5772/59360.
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two FDA approved BRAFi (vemurafenib and dabrafenib) selectively and potently block
the activation of BRAFV600E and thus inhibit the MAPK signaling pathway.
These drugs show very high clinical efficacy in metastatic melanoma patients
harboring the BRAFV600E mutation (12-14). Interestingly, in a clinical study which treated
43 patients with any V600 BRAF mutation including the rare V600R variant, five out of
the six melanoma patients having V600R mutation had clinical response to the therapy of
vemurafenib or dabrafenib (response rate 86%) (15).
However, wide type BRAF melanoma tumors do not respond to vemurafenib or
dabrafenib inhibition, although they are sensitive to the MEK inhibitors (10).
Paradoxically, in cells with RAS mutation and wild-type BRAF, treatment with
vemurafenib or dabrafenib will promote the formation of BRAF-CRAF heterodimer and
lead to the activation of subsequent MEK/ERK signaling and cell proliferation (5) as
shown in Figure 1-1. This mechanism is used to explain the observation of typical
clinical side effects associated with the use of vemurafenib: nearly 25% of patients
developed skin lesions and even cutaneous squamous cell carcinoma (CSCC). In
addition, in vitro study has revealed that vemurafenib inhibits multiple off-target kinases
including c-Jun N-terminal kinase (JNK), suppresses JNK-dependent apoptosis, and
generates CSCC toxicity (16).
1.2.1.2 Mechanisms of resistance to BRAF inhibition
In general, due to alternative pathway activations and inter- and intra-patients
melanoma genetic heterogeneity, various mechanisms of resistance to BRAF inhibition
have been identified (11, 17-20). As we mentioned before, melanoma tumors bearing
wide type BRAF are intrinsically resistant to vemurafenib and dabrafenib. Tumor microenvironment also contributes to the innate resistance to BRAF inhibition in melanoma.
For example, stromal cells secrete hepatocyte growth factor (HGF), which activates the
HGF-receptor MET, MAPK and PI3K-AKT pathways (21).
Eventually, nearly all BRAF mutated melanoma tumors develop acquired drug
resistance upon treatment with BRAF inhibitors. The disease progression arises as early
as two-month continuous treatment (19, 20). The mechanisms of acquired resistance to
BRAF inhibition can be generalized into two categories: BRAFV600E-bypass mechanisms
and MAPK-bypass mechanisms.
First, the BRAFV600E-bypass mechanisms reactivate MAPK signaling and lead to
ERK-dependent tumor cell survival and proliferation (Figure 1-2A). COT, which is
coded by gene MAP3K8, is a MEK kinase. The overexpression of COT or amplification
of MAP3K8 directly activates MEK signaling without the participation of RAF protein
(22). The mutant of MEK1C121S increases catalytic capability and circumvents BRAF to
activate basal level of ERK phosphorylation (23). Before the treatment of vemurafenib or
dabrafenib, melanoma cells with BRAFV600E mutation have over-activated monomer
BRAF/MEK/ERK cascade which forms an ERK-dependent negative feedback loop. This
negative feedback loop reduces the expression of the active RAS-GTP. In the presence of
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Figure 1-1. The mechanisms of BRAF inhibitor vemurafenib (Vem) action,
toxicity and the interaction between melanoma cells with T lymphocytes

3

Figure 1-2.

The mechanisms of acquired resistance to BRAF inhibition
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vemurafenib or dabrafenib, ERK phosphorylation level is rapidly reduced and the feedback suppression on RAS activation is abolished (Figure 1-1). Therefore, eventually the
ERK cascade level is restored through RAS over-activation. NRAS mutants including
NRASQ61K and NRASQ61R can drive ERK activation through ARAF or CRAF homo- or
hetero-dimers which are alternative MEK activators (24). The combinations of BRAF
inhibition plus MEK or ERK inhibition have showed efficacy of overcoming the
resistance through these BRAF V600E-bypass mechanisms (25-27), leading to the recent
FDA approval of dabrafenib plus trametinib combination therapy for advanced
melanoma.
Second, the MAPK-bypass mechanisms allow melanoma cells to escape from the
cytotoxicity of BRAF or MEK inhibition through the activation of ERK-independent
survival pathways (Figure 1-2B). The PI3K-AKT signaling pathway can be activated
through the overexpression of receptor tyrosine kinases (RTKs), for example, insulin-like
growth factor 1 (IGF-1) receptor (IGF-1R) and platelet-derived growth factor receptor
beta (PDGFRβ) (28). The elevated levels of IGF-1R, PDGFRβ or HGF can also stimulate
another receptor tyrosine kinase, MET, and increase the activity of PI3K. Phosphatase
tensin (PTEN) is a negative regulator of PI3K. The PTEN loss-of-function mutation
induces the resistance of BRAF inhibition and reduces the PFS of dabrafenib therapy in
melanoma patients due to the PI3K activation (29). Moreover, the up-regulation of cyclin
D1 can activate cyclin-dependent kinase 4 (CDK4) and 6 (CDK6) and make melanoma
cells less dependent on MAPK signaling in cell cycle progressing (30).
Additionally, Jaehyuk Choi et al has reported a BRAFL505H mutation which
changes an amino acid residue in BRAF-vemurafenib interface and causes the resistance
to vemurafenib treatment in vitro (31). Since vemurafenib is a substrate of the ATPbinding cassette sub-family G member 2 (ABCG2), the overexpression of ABCG2 in
BRAFV600E melanoma cell lines has caused the increasing of vemurafenib efflux in vitro
(32). The elucidation on the mechanism of acquired-resistance to BRAFi opens a door to
rationally design and explore the proper combination strategies to overcome or delay the
development of BRAFi resistance.
1.2.1.3 Targeting MEK: mechanism of action, toxicity and resistance
Trametinib, which was approved by FDA in May 2013 as a monotherapy agent
against advanced melanoma with BRAFV600E and BRAFV600K mutations, is a first-inclass, orally available, allosteric (non-ATP-competitive) MEK1/MEK2 inhibitor
(MEKi)(33, 34). It selectively inhibits MEK, the down-stream kinase protein of RAF in
the RAS-RAF-MEK-ERK pathway. As a result, melanoma cells with acquired resistance
to BRAFi are commonly cross-resistant to MEKi such as trametinib or selumetinib,
another selective allosteric MEKi (25, 35). This mechanism explains the clinical trial
results in which trametinib monotherapy fails to significantly benefit patients who have
already developed acquired BRAFi resistance (36). In contrast to the use of a BRAFi, no
CSCC side effects are observed among the patients received trametinib treatment in
clinical trials (14, 33). However, similar to the use of vemurafenib, disease progression
occurs within 6-7 months in patients receiving single-agent trametinib treatment (37).

5

Nevertheless, a retrospective analysis of 23 patients, who were first treated with MEKi
and upon progression with a selective BRAFi, shows that the median time to progression
(TTP) has been prolonged to 8.9 months from 4.8 months using a single-agent MEKi or
4.4 months for a single-agent BRAFi treatment, respectively (38). However, a recent
clinical trial indicated that if melanoma patients were treated with a BRAFi first then
MEKi therapy, no confirmed response was observed (36). This indicates that optimal
treatment schedule and sequence is important for the melanoma therapy targeting the
MAPK pathway.
1.2.1.4 Drug combination targeting MAPK pathway: from lab bench to
clinical practice
Given that the mechanisms of tumor cells develop resistance to BRAFi partially
by reactivating the ERK cascade and side effects such as CSCC are RAF-dependent,
combining BRAFi with MEKi has attracted lots of research interest in order to further
block the MAPK signaling pathway. In vitro and murine models first show the
synergistic anti-proliferation and anti-tumor growth effects using the combined BRAFi
and MEKi treatment (10, 28, 39, 40). Further, this combination overcomes the acquired
resistance to BRAFi (28, 39) in both cellular based assay and mouse xenograft models. In
addition, the combined inhibition of BRAF-MEK suppresses the paradoxical BRAFiinduced MAPK signal elevation in melanoma cells and reduces the incidences of skin
lesions in a rat model (10).
When it comes to the clinical trial data, the combined inhibition of BRAF-MEK
has presented significant improvements of major patient benefits (PFS and overall
survival). A phase I/II trial (ClinicalTrials.gov, NCT1072175) investigated the
combination of oral dabrafenib (150 mg twice per day) plus oral trametinib (1 or 2 mg
daily) (combination 150/1 and 150/2) versus monotherapy of dabrafenib (150 mg twice
per day) over 108 metastatic melanoma patients bearing either V600E (92 patients) or
V600K (16 patients) BRAF mutation (13, 37). Median PFS in combination 150/2 group
reached 9.4 months, compared to 5.8 months in the dabrafenib monotherapy group
(hazard ratio 0.39, 95% confidence interval 0.25 to 0.62). The incidence of CSCC
adverse events among combination 150/2 group is non-significantly lower than that
among monotherapy group (7% versus 19%, P = 0.09). But more frequent cases of
pyrexia which is not common in trametinib single treatment have been reported in
combination 150/2 group (71%, with recurrent rate 79%), as compared with dabrafenib
monotherapy group (26%) (41). These promising data lead to an accelerated FDA
approval of the combination of dabrafenib (BRAFi) and trametinib (MEKi) for the
treatment of unresectable or metastatic melanoma patients with BRAF V600E or V600K
mutation, although further phase III studies with recruitment of more patients comparing
the combination therapy with dabrafenib or vemurafenib single treatment
(ClinicalTrials.gov, NCT01584648, NCT01597908) are still being assessed.
In addition, several ongoing phase I/II clinical trials now have shown that
generally the combination of other BRAFi and MEKi is well tolerated in patients with or
without receiving BRAFi treatment before (ClinicalTrials.gov, NCT01271803
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vemurafenib (BRAFi) + cobimetinib (MEKi), NCT01543698 LGX818 (BRAFi) +
MEK162 (MEKi)) (42-44) and overall response rate has increased comparing to the
monotherapy groups, although the anti-tumor efficacy data haven’t been released.
1.2.2 Combination Targeted Therapy Using Phosphatidylinositol 3-kinase
(PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Inhibitors
The activation of PI3K/AKT/mTOR pathway have been widely proved to be one
of the major mechanisms of intrinsic or acquired resistance to both DNA-methylation
agents (e.g. dacarbazine) and targeted BRAF inhibitor therapy (Figure 1-1). Some cell
lines that are cross-resistant to both BRAFi and MEKi, are still sensitive to the inhibition
of AKT/mTOR(35). On the other hand, mechanistic study revealed evidences of a
negative crosstalk between RAF/MEK/ERK and PI3K/AKT/mTOR pathways through
RAS kinase. Therefore, when the downstream mTOR function is blocked, PI3K will be
able to activate MAPK pathway via a switch of RAS (45, 46). These investigations
suggest a promising combination strategy of targeting MAPK pathway together with
PI3K/AKT/mTOR cascade. Several preclinical studies widely proved that in MAPK
inhibition sensitive melanoma cell lines, co-targeting PI3K/AKT/mTOR effectively
induces cancer cell apoptosis with down-regulated anti-apoptotic BCL-2 family proteins
(35, 47-49). Such a co-targeting strategy can also postpone the emergence of acquired
resistance to BRAFi dabrafenib mediated by PTEN mutation or disruption (50, 51).
Further, the dual inhibition of two pathways has successfully overcome NRAS mutation
mediated resistance to MAPK blockade in vitro and induced xenograft tumor regression
in vivo (35, 39, 52). Finally, the combination of vemurafenib (BRAFi) or selumetinib
(MEKi) with BEZ235 (dual PI3K and mTORc1/2 inhibitor) has been shown to overcome
the PDGFRβ-driven resistance to MAPK pathway inhibition (53).
A series of Phase I studies have evaluated the clinical relevance of the
combination therapy which co- targets PI3K/AKT/mTOR and RAF/MEK/ERK pathways
in terms of the incidence on severe side effect and anti-tumor efficacy in 236 patients.
These patients have advanced cancers including melanoma, colorectal, pancreatic and
non-small cell lung cancers. Results from three combination groups (AKTi MK2206 +
MEKi selumetinib, NCT01021748; AKTi GSK2141795 + MEKi trametinib,
NCT01138085; mTOR inhibitor everolimus + MEKi trametinib, NCT 00955773) are
compared to the single treatment groups (54). Overall, the combination therapy did not
provide significant increase of tumor control rate (64.6% for combination, 52.7% for
monotherapy, P = 0.16), although all five colorectal patients with co-activation of both
pathways in combination group achieved tumor regression to varied extent between 2%
and 64%. However, this combination strategy causes significant higher rates of drugrelated grade III and above side effects (53.9% for combination, 18.1% for monotherapy,
P < 0.001). Furthermore, two clinical trials which involve the combination therapy of
BRAFi or MEKi with AKTi DNE3 recently have been terminated due to the safety
concerns of the toxic properties of DNE3 (ClinicalTrials.gov, NCT02087254 and
NCT02095652). Nevertheless, in another ongoing phase I/II trial which measures the
safety and efficacy of a well-tolerated pan-PI3K inhibitor BKM120 combined with

7

vemurafenib therapy, preliminary data reveals that a vemurafenib-refractory melanoma
patient with PTEN expression achieved a 35.9% reduction in target tumor
(ClinicalTrials.gov, NCT01512251) (55). In general, drug-related toxicity is one of the
major issues for this cross-pathway targeted combination therapy and patients genetic
profiling is very important to achieve the maximum objective response.
1.2.3 Combining Targeted Therapy with Anti-angiogenic Agents
Melanoma is a vascular tumor. The abnormal expression of the epidermal growth
factor (EGF) family protein and the up-regulation of EGFR-mediated alternative survival
pathway have critically shaped the response of melanoma to the current chemotherapy
agents (56-59). In a recent study by Sun et al, six out of sixteen melanoma cell lines
display acquired EGFR expression after the development of resistance to BRAFi and
MEKi (60). Even before the FDA approval of BRAFi and MEKi, the combination of
bevacizumab, a recombinant human monoclonal antibody VEGF inhibitor, with a
specific chemotherapy agent (for example, fluorouracil (61) or fotemustine (62)), has
become a first-line treatment for metastatic melanoma patients. Clinical trials that study
the combination of anti-angiogenic agents with cytotoxic agents have achieved promising
anti-tumor activity, although tolerability issues exist (63). VEGF blockage has been
shown to enhance the efficacy of a GM-CSF-secreting immunotherapy in vitro (64). In
addition, a VEGF receptor-2 inhibitor, semaxanib, prolonged both the complete and
partial response time of an immunomodulatory drug, thalidomide, over 10 recurrent
metastasis melanoma patients without showing significant drug-drug interaction toxicity
in a phase II trial (65).
Along with the rapid development of targeted melanoma therapeutics, the
combined inhibition of VEGFR plus PDGFR or mTOR has shown synergy anti-tumor
effects on mouse models of B16 metastatic melanoma without increasing toxicity (66,
67). A large-scale, unbiased drug screening study, which aims to discover effective
genotype selective combinatorial therapeutics of vemurafenib-resistant BRAF and RAS
mutant melanoma, identifies a triple BRAF+EGFR+AKT inhibition as highly effective
approach (3). In the year of 2010, combination of bevacizumab with an mTOR inhibitor,
everolimus, was evaluated in a phase II trial for patients with metastatic melanoma (68).
The treatment was well tolerated in most patients. Seven out of fifty-seven patients (12%)
receiving combination therapy have shown major responses, although the median PFS
was only 4 months. This year (2014), in a phase II trial that combines bevacizumab and
sorafenib, which is an inhibitor of both RAF kinase and VEGFR-2/PDGFR-β signaling,
no objective tumor responses are seen in all the fourteen patients receiving treatment (69,
70). Interestingly, the median TTP of patients with low VEGF (<300 pg/ml) was longer
than that of patients with high VEGF (50 weeks versus 15 weeks, P =0.02). Therefore,
the levels of VEGF in patients do influence the tumor progression profile
(ClinicalTrials.gov, NCT00387751).
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1.2.4 Combination Therapy Using Targeted Therapy with Versatile Chemotherapy
Agents
Since the abnormally activated (phosphorylation) of ERK and AKT constitutively
exist in melanoma cells and promote the disease progression especially metastasis,
blocking ERK or AKT pathway can sensitize the metastatic melanoma to the apoptosis
induced by chemotherapeutic agents including cisplatin, temozolomide, DTIC and
arsenite (71-73). With the understanding of tumor biology about the programmed cell
apoptosis and the rapid development of agents that can trigger the cell death process in
melanoma, the combination of a MAPK inhibitor with a BCL-2 inhibitor (ABT-737 (74)
or navitoclax (75)), or a MDM2 antagonist nutlin-3 (76), has synergistically induced
apoptosis of melanoma in vitro and suppressed xenograft tumor growth in vivo. A
comparative analysis on the samples collected from patients receiving vemurafenib or
dabrafenib/trametinib combination treatment showed that BCL-2 expression level is
closely related to the onset of MAPK inhibition resistance (75). Clinical trials are being
conducted to investigate the combination of BCL-2 inhibitor (BH3 mimetics) navitoclax
and vemurafenib (75).
Due to the heterogenetic characteristics of melanoma disease, Vultur A et al (77)
recently report that MEK or BRAF inhibition can potentially strengthen the invasion
property of human melanoma cells by about 20%. As a result, co-inhibiting kinases that
are actively involved in cell invasion process, such as RTK, STAT3 and Src, together
with MEK inhibition has effectively abolished the invasive phenotype and further caused
the tumor cell death in a 3D matrix model.
Metformin, a biguanide oral anti-diabetic drug, has been discovered with
antitumor activity in various cancer types including melanoma. Although the exact
mechanisms remain to be elucidated, accumulating data suggest that metformin can
activate AMP-activated protein kinase (AMPK) and thus increase the activities of VEGF
and ERK in BRAFV600E mutated melanoma cells (78). AMPK negatively regulates
malignant cell proliferation and viability (79). The combination of vemurafenib and
metformin has shown synergistic anti-proliferative effects on six out of eleven tested
BRAFV600E melanoma cell lines (80). Pilot clinical studies that evaluate the safety and
efficacy of metformin combination therapies (plus dabrafenib or trametinib) are now
recruiting patients (ClinicalTrials.gov, NCT0184000, NCT02143050).
Unlike the cutaneous melanoma, over-activation of MAPK pathway in uveal
melanoma is associated GNAQ or GNA11 mutations instead of BRAF or RAS mutations
(81). Protein kinase C (PKC) inhibitors such as enzastaurin or AEB071 induce apoptosis
in GNAQ-mutant but not in GNAQ wild type uveal melanoma cells (82). The level of
ERK phosphorylation also decreases in these cells when they are treated using PKC
inhibitors (82). Chen et al. has recently confirmed the synergy of the combination using a
PKC inhibitor with a MEKi (PD0325901 or MEK162) in GNAQ/11 mutant uveal
melanoma cells (83).
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Understanding the mechanisms of resistance to MAPK inhibition in melanoma
can lead to rational combination designs in order to overcome acquired drug resistance to
BRAF inhibitors. For example, our lab recently identified a synergistic combination in
which a novel tubulin inhibitor ABI-274 combined with vemurafenib could overcome the
acquired vemurafenib-resistance (84). This combination treatment effectively arrested the
vemurafenib-resistant melanoma cells in both G0/G1 and G2/M phases and induced strong
apoptosis through the down-regulation of AKT phosphorylation. In addition, the
combination of a MEKi (TAK-733) with an Hsp90 inhibitor (ganetespib) induces tumor
regressions in vemurafenib-resistant xenograft models also through the depletion of AKT
signaling (85). With the finding that up-regulated cyclin D1 expression is critical for the
survival of vemurafenib-resistant cells, a selective inhibitor of cyclin dependent kinase
(CDK) 4/6, LY2835219, has been reported to overcome the reactivation of MAPK
signaling in vemurafenib-resistant BRAFV600E melanoma (86).
1.3 Combinations Involving Immunotherapy in Melanoma Treatment
1.3.1 Combined Blockade of Immuno-checkpoints
Given the unsatisfactory results of cytokine-based melanoma immunotherapy
(recombinant interferon-α 2b and high dose interleukin-2) in the past decade, the
development and approval of ipilimumab (anti-cytotoxic T lymphocyte-associated
antigen 4 (CTLA-4) monoclonal antibody) in 2013 have marked a breakthrough of
immune-checkpoints blockade therapy (87). CTLA-4 (CD152) expresses on the surface
of active T-lymphocytes and inhibits the initial T-cell proliferation and migration to the
tumor tissue (88). CTLA-4 antibodies preferentially target the suppressive regulatory T
cells and prevent them from being hijacked by tumors (89). In a double-blinded phase III
study in 676 patients with pretreated and refractory metastatic melanoma, ipilimumab at
the dose of 3 mg/kg achieved a median OS of 10 months (87). In a meta-Kaplan-Meieranalysis of data collected from 1,861 melanoma patients in a clinical trial, a plateau of
survival curve starts from around 3 years after ipilimumab treatment with follow-up
extends as long as ten years, indicating a long-term survival benefits of ipilimumab
therapy (ClinicalTrials.gov, NCT01844505). In addition, ipilimumab showed good
tolerance and efficacy in several other clinical trials in which it was combined with a
standard chemotherapy agent such as dacarbazine, fotemustine or temozolomide (90).
Another success of immune-check point blockade strategy is the development of
anti-programmed death-1 (PD-1) antibodies, represented by pembrolizumab (MK-3475)
and nivolumab (91, 92). Pembrolizumab, as the first-in-class PD-1 inhibitor, has obtained
FDA approval in September 2014 for patients with advanced or unresectable melanoma.
The cDNA of PD-1 (CD279) is first cloned in programmed death T cells although PD-1
itself does not directly induce apoptosis. PD-1 is over-expressed on the surface of
dysfunctional activated T-cells and contributes to the maintenance of T cell dysfunction
(exhaust) phenotype and proliferation disability in the tumor site (93). Two counter
receptors of PD-1 have been identified: PD-L1 and PD-L2. PD-L1 is more frequently and
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exclusively expressed in various tumor cells; therefore, antibodies targeting PD-L1
(MPDL3280A and BMS-936559) also have anti-tumor activity in advanced cancer
including melanoma (92, 94). The PD-1-PD-L1 ligation retards the recognition and
destroying of tumor cells by CD8+ cytotoxic T-lymphocytes (88). As a result, blocking
PD-1 or PD-L1 will reverse the cancer cell immune escape. Because both CTLA-4 and
PD-1 are key negative receptors that cooperatively modulate the adaptive immune
response in tumor progression, their combination has been shown to be synergistic in B16
melanoma tumors without overt toxicity (95).
In a cohort phase I trial that studied the concurrent administration of ipilimumab
and nivolumab to 53 patients with advanced, treatment-resistant melanoma, more than
80% tumor reduction was observed in 30% patients after 12 weeks treatment at the
maximum tolerated dose. Twenty-one out of fifty-three patients had objective responses
and over 80% of these patients had tumor regression. Grade 3/4 adverse events are
diagnosed in 53% patients but the toxicities are manageable with immune-suppressants
(96). Consequential trials with more enrollment number of patients are necessary to
further evaluate the safety and efficacy of this promising double immune-checkpoints
blockage therapy comparing with each of its monotherapy regiments.
Finally, combinatorial clinical trials using ipilimumab with other immunotherapy
agents have shown some favorable therapeutic benefits. For example, combination of
ipilimumab with peginterferon α-2b (pegylated interferon α-2b) in patients with
unresectable melanoma both demonstrated significant increase of response rate and OS
comparing with the monotherapy arm (97, 98) in recent phase I trials.
1.3.2 Combined Therapy Inhibiting both Immuno-checkpoint and MAPK Signaling
Pathway
Checkpoint blockade immunotherapy and MAPK targeted chemotherapy have
distinct clinical profiles. For example, targeted therapy has relative higher initial response
rate (~60% for BRAFi) with rapid onset of effect, but its efficacy restrictively rely on the
continuous treatment and the therapeutic response is usually not durable due to the quick
development of acquired drug resistance. In contrast, immunotherapy has much a lower
response rate (4.5% for ipilimumab), delayed onset of effect and difficulty in predicting
patient outcome, but it has shown potentially durable responses and long-term survival
benefit even off treatment. In addition, since the MAPK pathway is not required in the
process of anti-tumor immune response, blocking MAPK signaling should not interfere
with the efficacy of checkpoint blockade immunotherapy. Therefore, it seems very
rational that the combination of a MAPKi and an immunotherapy agent such as
ipilimumab or pembrolizumab can maximize the therapeutic benefits in advance
melanoma.
Interestingly, BRAF and MEK inhibition displayed an “endogenous vaccine-like”
effects in melanoma cells (99). Cytotoxic agents like BRAFi induce tumor cell death and
promote the uptake and presentation of tumor antigens to the effector immune cells (T
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cells and B cells) through antigen-presenting cells (55). MEK inhibition, BRAFV600E
RNA silencing or BRAF inhibition by PLX4720 increases the CD4+ and CD8+
lymphocytes mediated T-cell infiltration and reduce the level of immune-suppressants
including IL-6, IL-10 or VEGF (100-102) in mice. The expression of PD-L1 is found to
be elevated in BRAFi-resistant melanoma cells and it is mediated through the off-target
activity of BRAFi in JUN and STAT3 signaling (103). However, Vella et al has
published a paper in 2014 and stated that they have not found any impact of dabrafenib
treatment on T lymphocytes. trametinib alone or in combination with dabrafenib has
suppressed T lymphocyte proliferation, cytokine secretion and antigen-specific expansion
in their isolated T lymphocyte and monocyte-derived dendritic cells. These findings
should be carefully tested in vivo to evaluate the clinical relevance (104).
As for the clinical practice, dose-limiting hepatotoxicity issues have led to the
premature termination of the first phase I study on combination of ipilimumab with
vemurafenib (ClinicalTrials.gov, NCT01400451). This signified the complexity of
adverse effect in combined therapy of immune-regulating agents and kinase inhibitors.
Another phase I study of ipilimumab plus dabrafenib, or ipilimumab plus the
combination of dabrafenib with trametinib is still active and a phase II study is exploring
the safety and efficacy of sequential administration of vemurafenib followed by
ipilimumab (ClinicalTrials.gov, NCT01767454, NCT01673854). The data of these most
recent trials will be released in the near future.
1.4 Conclusion
Extensive efforts and remarkable progresses have been made to discover and
investigate rational approaches in combination melanoma therapy since the recent
approval of MAPKi and immune checkpoints blockade antibodies. A number of new
targeted or immune drugs for metastatic melanoma are currently under commercial
development or late stage clinical trials, some of which will likely be approved in the
next few years. Quality of life for many melanoma patients has been dramatically
increased. However, significant challenges still remain. While some clinical evidence has
really raised the expectation of survivals for patients with advanced melanoma, the
benefits of combination therapy are usually accompanied by limitations. Comprehensive
genetic profile and tailored patient matching is essential for targeted therapy, while
biomarkers are critical to predict the patient immunotherapy response. Drug-related
toxicity for combination treatment usually is not a simple one-plus-one situation, and
potential drug-drug interactions, especially the combination of a targeted agent with an
immunotherapeutic agent must be carefully evaluated in order to achieve both fast and
durable responses. Adverse effects should be closely monitored and potential alternative
dosing regiments is worth further exploration. Optimized dose schedule may help to
delay the resistance development and reduce the frequency of adverse effect. For
example, intermittent doses of BRAFi was able to enhance the tolerance in combination
with immunotherapy, decrease the paradoxical MAPK activation, which might be the
main cause of severe toxicity in clinical trial (105). Solid evidence of synergistic
combination in preclinical research must be established before clinical trial conduction.
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In fact, with the relatively large number of available targeted agents and
immunotherapeutic agents for metastatic melanoma, the huge number of possible drug
combinations coupled with dosing sequences or schedules already presents a significant
challenge in designing proper clinical trials. To test all the possible drug combinations
along with different dosing sequences clinically will not only have low benefits to
patients, but is also a huge financial burden to the society. Carefully designed, predictive
preclinical studies will be essential to provide critical supports for rational prioritization
of clinical trials using drug combinations. Finally, clear understandings of various
combination mechanisms and patient genetic profiles are critically important for the
development of new combination approaches, prediction of expected therapy response
and potential side effects. With the rapid advances in this field, it is likely that optimal
combination treatments will greatly improve the management of advanced melanoma in
cancer patients.
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CHAPTER 2. OVERCOMING ACQUIRED RESISTANCE TO BRAF
INHIBITORS BY NOVEL SYNERGISTIC DRUG COMBINATION*
2.1 Introduction
The sustained clinical activity of vemurafenib in melanoma patients with
BRAFV600E mutation is limited by the rapid development of acquired resistance (106108). Several mechanisms have been proposed in the literature (28, 109-111), including
the amplification of the BRAF oncogene (112), the up-regulation of CRAF expression
(113), oncogenic activation of NRAS (114), up-regulated EGFR-SFK-STAT3 pathway
(115), gatekeeper mutations (116-118), up-regulation of growth factor receptors such as
insulin-like growth factor 1 receptor (IGF1R) (46) or platelet-derived growth factor
receptor (PDGFR) (114), and other resistance mechanisms (21, 119). Several methods to
maintain phosphorylated extracellular-signal-related kinase 1 and 2 (p-ERK1/2) levels in
the presence of BRAF inhibitor drugs have been described, including ERK-kinase 1
(MEK1) mutation, recruitment of alternative MEK1/2 activators, RAS mutation or upregulation of receptor tyrosine kinases (RTKs). Thus in many cases, vemurafenibresistant cells are cross-resistant to MEK inhibitors (35, 109, 120).
Drug combinations using agents with distinct anti-cancer mechanisms can
enhance tumor response and patient survival, especially in the treatment of advanced
cancer patients (121-123). Combinations of vemurafenib with agents targeting the same
mitogen-activated protein kinase (MAPK) pathway such as MEK or ERK inhibitors show
clinical efficacy (28, 37, 39, 124), however they can only arrest cells in the G0/G1 phase.
Such combination strategies are unlikely to be effective against resistant cells that can
escape from this cell cycle arrest. Our preliminary study showed that the chronically
selected vemurafenib-resistant human melanoma cells could not be blocked in the G0/G1
phase by vemurafenib at the effective concentration to sensitive parental cell line, and the
vemurafenib-resistant cells readily progressed into the G2/M phase. Thus, we
hypothesized that a combination of vemurafenib with a compound that strongly induces
the subsequent G2/M phase block should capture vemurafenib-resistant cells leaking from
G0/G1 arrest, and thus produce a strong synergy.
We recently discovered a novel class of anti-mitotic agents, represented by the 2aryl-4-benzoyl-imidazoles (ABIs) scaffold (125-128). ABI-231 and ABI-274 are among
our most potent ABI compounds discovered to date with anti-proliferation IC50 values in
the low nanomolar (nM) range in several melanoma cell lines. They bind to tubulin at the
colchicine binding site (129).

*Modified with permission. Wang J, Chen J, Miller DD, Li W. Synergistic combination
of novel tubulin inhibitor ABI-274 and vemurafenib overcome vemurafenib acquired
resistance in BRAFV600E melanoma. Mol Cancer Ther. 2014;13: 16-26.
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Compared with many existing tubulin inhibitors such as paclitaxel and
vinblastine, ABIs can effectively circumvent several clinically relevant multidrug
resistant mechanisms, including drug resistance mediated by P-glycoprotein (Pgp),
multidrug resistance-associated proteins (MRPs), and breast cancer resistant proteins
(BCRP). An in vivo study indicated that ABIs significantly inhibited melanoma lung
metastasis in mice (129). In the current study, we tested our hypothesis of synergistic cell
cycle arrest by the combinations of vemurafenib with ABIs or docetaxel in a panel of
BRAFV600E mutant parental melanoma cell lines and chronically selected vemurafenibresistant A375RF21 and MDA-MB-435 VemR sublines (28). The established
vemurafenib-resistant A375RF21 cells were used in vitro and in vivo as the disease
relapse model to test whether our proposed synergistic drug combination would be of
potential therapy benefit in associated clinical vemurafenib resistance.
2.2 Materials and Methods
2.2.1 Reagents and Cell Lines
Vemurafenib, selumetinib, trametinib, sunitinib (malate salt) and docetaxel were
purchased from LC Laboratories (Woburn, MA). ABI-274 was synthesized as described
(126). Human melanoma A375 cell line was acquired from ATCC (Manassas, VA).
Human melanoma WM164 and MDA-MB-435 cells were obtained from Dr. Meenhard
Herlyn (Wistar Institute, Philadelphia, PA), and Dr. Robert Clarke (Georgetown
University, Washington, DC), respectively. MEK inhibition resistant 451LuMR and
BRAF inhibition resistant WM983B BR cells were gifts from Dr. Meenhard Herlyn
(Wistar Institute, Philadelphia, PA). All cell lines were authenticated prior to use for this
study. A375, WM164 and MDA-MB-435 cells were cultured in DMEM medium
(Mediatech, Inc., Manassas, VA), supplemented by 10% fetal bovine serum (FBS,
Atlanta Biologicals, Lawrenceville, GA), 1% antibiotic/antimycotic mixture and 5 μg/mL
bovine insulin (Sigma-Aldrich, St. Louis, MO). 451LuMR and WM983B BR cells were
maintained in 5% FBS supplemented DMEM medium with 1 μM trametinib or
vemurafenib, respectively.
Vemurafenib-resistant melanoma cells were chronically selected by culturing
A375 or MDA-MB-435 cells in increasing concentrations of vemurafenib following the
reported method (28) for at least three months. A375RF21 and MDA-MB-435 VemR
cells are maintained in full growth medium containing 2.5 μM vemurafenib.
2.2.2 Cell Proliferation and In Vitro Combination Assay
Cell proliferation was investigated using the MTS or SRB assay as described
previously (125, 126, 129). An in vitro study of the combination of vemurafenib and the
tubulin inhibitors was designed and conducted using CalcuSyn software (Biosoft,
Ferguson, MO) with five duplicates of each treatment set. Drug concentrations were
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selected based on the IC50 value of each drug tested from a pilot study. Synergism,
additive activity or antagonism was determined through the Chou-Talalay method (130),
showing a combination index (CI) as calculated in the software output.
2.2.3 Cell Cycle Analysis
Flow cytometry analysis was performed as described before (129). To determine
cell cycle distributions in the G2 and M phases, cells were harvested with trypsin, stained
using anti-phospho-histone H3 - AlexaFluor® 488 antibody on ice for one hour in the
dark, followed by stained using PI/RNase solution for 30 minutes at room temperature in
the dark per the manufacturer’s instructions (#FCCH025103, EMD Millipore
Corporation, Ballerica, MA). Data were further processed and graphs were prepared
using the Modfit 2.0 program (Verity Software House, Topsham, ME).
2.2.4 Tubulin Polymerization Assay
HTS-tubulin polymerization assay was performed as described previously (127)
using a commercial kit following the manufacturer’s instructions (#BK004P,
Cytoskeleton, Inc., Denver, CO). The absorbance at 340 nm was kinetically recorded
every 1 min for 45 min at 37 °C by the SYNERGY HT micro-plate reader (Bio-Tek
Instruments, Winooski, VT).
2.2.5 Western Blot Analysis
At the indicated time treatment, A375RF21, MDA-MB-435 VemR, A375, MDAMB-435 or WM164 cells were collected to investigate levels of relevant cascade protein
or apoptosis markers by western blots. The following primary rabbit antibodies (Cell
Signaling Technology, Inc., Danvers, MA) were used: anti-phospho-ERK1/2
(Thr202/Tyr204; #9101), anti-p44/42 MAPRK (ERK1/2; #9102), anti-phospho-AKT
(Ser473; #9271), anti-AKT (#9272), anti-cyclin D1 (#2978); anti-cleaved PARP (#9185),
anti-cleaved caspase-3 (#9664), anti-RAS (#3339), anti-ARAF (#4432), anti-BRAF
(#9433), anti-CRAF (#9422), phosphor-PI3 kinase p85 (Tyr458)/ p55 (Tyr199) (#4228),
anti-PTEN (#9188), anti-PDGF receptor β (#3169), or anti-GAPDH (#3683). Target
proteins were detected by incubating with 1× LumiGLO® reagent (Cell Signaling, #7003)
for one minute and exposed to x-ray film. The films were scanned with grey scale and
lane intensities were quantified with the ImageJ software (NIH, Bethesda, MD, USA).
2.2.6 Apoptosis Detection
A375RF21 cells were seeded in 6-well plates (1 × 106 per well) and treated with
growth medium containing 0.5% DMSO, vemurafenib, ABI-274, docetaxel or the
indicated combinations. After 48 hours of incubation, apoptosis analysis was performed
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using the Annexin V-FITC Apoptosis Detection Kit (Abcam, Cambridge, MA) as per
manufacturer’s instructions and analyzed by a BD LSR-II cytometer (BD Biosciences,
San Jose, CA).
2.2.7 Vemurafenib-resistant Tumor Xenograft and Treatment
Seven to eight week old male nude mice were purchased from Charles River
Laboratories International, Inc. (Wilmington, MA). A375RF21 cells were suspended in
ice-cold phenol red-free and FBS-free DMEM medium and mixed with high
concentration Matrigel (BD Biosciences, San Jose, CA) at a ratio of 1:1 right before use.
100 μL of this mixture containing 3 × 106 cells was injected subcutaneously (s.c.) to the
left-side dorsal flank of each mouse. One week after the inoculation, the mice were
randomized into four groups (n = 7 for the initial low dose and n = 5 for subsequent high
dose drug combination) and the treatments started. ABI-274 or vemurafenib was diluted
in PEG300 (Sigma-Aldrich, St. Louis, MO) and administered through intraperitoneal
(i.p.) injection once per day, 5 days per week for three continuous weeks. Vehicle control
group was i.p. injected with same volume (100 μL) of PEG300 at the same dosing
frequency. At the end of the experiments, mice were euthanized and tumor tissues were
isolated, weighted and then fixed in 10% buffered formalin phosphate solution.
Tumor volume and body weight of each mouse were evaluated three times a week.
We calculated the tumor volume using formula a × b2 × 0.5, where a and b
represented the larger and smaller tumor diameters (129). Data was showed as mean ±
SD for each group and plotted as a function of time. Tumor growth inhibition (TGI) was
calculated as 100 – 100 × [(T - T0)/(C - C0)], and tumor regression was calculated as (TT0)/ T0 × 100, where T, T0, C and C0 are the mean tumor volume for the specific group on
the last day of treatment, mean tumor volume of the same group on the first day of
treatment, mean tumor volume for the vehicle control group on the last day of treatment
and mean tumor volume for the vehicle control group on the first day of treatment,
respectively (28, 107).
2.2.8 Pathology and Immunohistochemistry (IHC) Analysis
Tumor tissues fixed in formalin buffer for over one week were stained with
hematoxylin and eosin. For IHC analysis, the following primary antibodies were used:
rabbit anti-Ki67, anti-phospho-AKT (Ser473), and anti-phospho-ERK1/2
(Thr202/Tyr204) (#9027; #4060; #4376, Cell Signaling Technology). Anti-S100 primary
antibody was purchased from Abcam (#ab868, Abcam Inc., Cambridge, MA). Analyses
were performed following manufacturer’s protocols.
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2.2.9 Statistical Analysis
Data were analyzed using Prism Software 5.0 (GraphPad Software, Inc., San
Diego, CA). The statistical significance (P < 0.05) was evaluated by Mann-Whitney
Rank Test, nonparametric t-test and one-way ANOVA for in vitro apoptosis detection
and xenograft study. Treated groups were compared with the vehicle group and
combination treatment groups were compared with the groups that received single agent
treatment, accordingly.
2.3 Results
2.3.1 Combination of Vemurafenib with ABI Compound Showed Strong Synergies
in Parental BRAFV600E Mutant Melanoma Cell Lines
We started by testing ABI compounds (ABI-231 and ABI-274) to evaluate their
combination effects with vemurafenib on parental human A375, MDA-MB-435 and
WM164 cells which were all BRAFV600E mutant cell lines. Two well-known tubulin
inhibitors, docetaxel and colchicine, were included for comparison (Table 2-1). We
found that calculated CI values for combinations of ABI-231 or ABI-274 and
vemurafenib was as low as 0.22 (in A375 cell line) and 0.10 (in MDA-MB-435 cell line)
at ED50, showing the combination treatment had strong synergistic effects in vitro.
2.3.2 Combination of ABI-231 and Vemurafenib Produced Synergistic Cell Cycle
Arrests in Vemurafenib-sensitive A375 Cells
ABI compounds as novel tubulin inhibitors arrest cancer cells including human
melanoma A375 at G2/M phase, but vemurafenib as a BRAF inhibitor blocks cancer cell
progressing from G1 phase. As shown in Figure 2-1, cell cycle distribution quantitative
data revealed that single treatment of ABI-231 at 20 nM generated 43 ± 8% or 70 ± 2%
of G2/M arresting after 12 h or 24 h incubation. And 60 ± 4% or 91 ± 1% cells were
accumulated in G1 phase when they were treated by vemurafenib at 2 μM for 12 h or 24
h. The combination of compound ABI-231 with vemurafenib displayed interesting
“double” cycle cell arresting pattern at both G1 and G2/M phases in A375 cells from 12 h
incubation, which contributed to the combined synergistic anti-proliferation effects.
2.3.3 Combination of ABI-231 and Vemurafenib Affected Related Protein Levels in
Vemurafenib-sensitive A375 Cells
To preliminarily investigate the mechanism of synergy combination, we
performed western blotting to check the levels of related proteins in A375 cells after
either single or combined treatment for 24 h, comparing with the DMSO vehicle control
group. Representative results are shown in Figure 2-2. Since A375 is a vemurafenib-
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Table 2-1.
Combination of vemurafenib with tubulin inhibitors showed
synergistic effect in the parental BRAFV600E melanoma cell lines as indicated by CI
values determined at ED50
Treatment
+vemurafenib

A375

MDA-MB-435

WM164

ABI-231

0.22

0.23

0.66

ABI-274

0.32

0.10

0.61

Docetaxel

0.50

0.55

0.54

Colchicine

0.47

0.78

1.28

The combination index (CI) values at ED50 were calculated based on the results from cell
viability MTS assay (n = 5). CI < 0.9 indicates synergism; 0.9 ≤ CI ≤ 1.1 indicates
additive effect; CI > 1.1 indicates antagonism between the two tested drugs.
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Figure 2-1. Cell cycle analysis of A375 cells incubated with single or combination
treatment for 24 h (n = 3)
A, representative flow cytometry diagram of cell cycle distribution. B, quantitative results
of cell phase distribution. Data is presented by mean ± S.D.
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Figure 2-2. Representative images of western blotting results for A375 cell
incubated with either single or combination treatment for 24 h
The densitometry data was measured by ImageJ software and normalized according to
the reading from beta-actin loading control groups.
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sensitive cell line, the treatment of vemurafenib or combination greatly reduced the level
of pERK due to the inhibition of upstream BRAF activity. But ABI-231 single treatment
did not affect the level of ERK phosphorylation. Interestingly, AKT phosphorylation
level, which is critical in the regulation of cell survival and apoptosis, was reduced in
both ABI-231 single treatment and combination treatment group. And the reduction of
pAKT in these two groups accompanied with the decrease of total AKT level. This
observation indicates that compound ABI-231 as a tubulin polymerization inhibitor exerts
its anti-cancer activity partially through the interference of AKT pathway. And the coinhibition of both ERK and AKT phosphorylation generated synergistic anti-proliferation
effect in vitro.
2.3.4 Establishment of Vemurafenib-resistant A375RF21 Melanoma Subline
Clinically melanoma tumors inevitably relapse only 3 to 6 months after receiving
vemurafenib chemotherapy, and therefore we wanted to determine whether the observed
synergy will remain effective in vemurafenib-resistant cells. Towards this goal, we
established vemurafenib-resistant A375RF21 subline from the parental A375 human
melanoma cells by chronic selection following literature reported procedures (28). The
isolated resistant A375RF21 cell line steadily increased IC50 values for vemurafenib over
50 fold (28.9 ± 0.6 μM in A375RF21 cells compare to 0.57 ± 0.03 μM in the parental
A375 cells, Figure 2-3).
We performed western blot analyses using both A375 and A375RF21 cells to
determine differential protein activations known to result in vemurafenib resistance. As
shown in Figure 2-4A, the pERK level in A375RF21 in the presence of 2.5 μM
vemurafenib (maintenance concentration of its culture medium) does not change,
confirming the development of acquired vemurafenib resistance.
The pMEK expression also remains active in A375RF21 cells, indicating their
potential cross-resistance to MEK1/2 inhibitors. We confirmed this cross-resistance by
incubating cells with two known MEK inhibitors (trametinib and selumetinib, Figure
2-4B and C). The PI3K/AKT pathway was over-activated in A375RF21 cells while no
significant changes of RAS, BRAF, ARAF, CRAF levels were observed. These results
are consistent with the report of Fei Su et al (28). Interestingly, we found that the level of
PDGFRβ also increased significantly in A375RF21 cells in the presence or absence of the
2.5 μM vemurafenib maintenance medium. Both resistant mechanisms that confer drug
resistance in A375RF21 cells are well known to exist in vemurafenib-resistant patient
tumors.
2.3.5 Combination of Vemurafenib with ABI-274 Showed Strong Synergies in
Vemurafenib-resistant A375RF21 Melanoma Cell Lines
As shown in Table 2-2, the drug combination study when repeat using A375RF21
cells produced calculated CI values for ABI-231 or ABI-274 in combination with
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Figure 2-3. Establishment of vemurafenib-resistant A375 melanoma cell line
A375RF21 from its parental A375 cell line using chronic selection over 3 months
with increasing concentrations of vemurafenib
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Figure 2-4. Major vemurafenib resistance mechanisms in A375RF21 cells are the
over-expression of PDGFRβ and the activations of the PI3K-AKT pathway
A, western blot analyses to compare the differential protein levels in the sensitive
parental A375 and the vemurafenib-resistant A375RF21 cells, in the presence or absence
of 2.5 μM vemurafenib (A375RF21 cell culture maintenance concentration). Cells were
incubated with control vehicle or 2.5 μM vemurafenib for 24 h. Phospho-PI3K level was
determined after 30 minutes stimulantion with 30 μM hydrogen peroxide. Graph showed
representative results of three independent experiments. B, growth inhibition efficacy of
kinase inhibitors determined in MTS assay (n = 4) on A375 and A375RF21 cells.
Trametinib and selumenitib are MEK inhibitors while sunitinib (malate salt) is an RTK
inhibitor. C, comparison of calculated IC50 values (showed as mean ± SD).

24

Table 2-2.
Combination of vemurafenib with tubulin inhibitors showed
synergistic effect in the vemurafenib-resistant A375RF21 melanoma cell lines
Treatment
+vemurafenib
ABI-231

CI at ED50

CI at ED75

CI at ED90

0.44

0.56

0.65

ABI-274

0.53

0.59

0.70

Docetaxel

0.63

0.80

0.90

Colchicine

0.84

0.94

1.36

The combination index (CI) values were calculated based on the results from cell
viability MTS assay (n = 5). CI < 0.9 indicates synergism; 0.9 ≤ CI ≤ 1.1 indicates
additive effect; CI > 1.1 indicates antagonism between the two tested drugs.
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vemurafenib that were all less than 0.9 (range: 0.44-0.70), indicating strong synergy in all
concentrations tested. At ED50, all tubulin inhibitors acted in a synergistic manner with
vemurafenib. With an increase in drug concentration, the CI values for docetaxel or
colchicine groups increased relatively quickly. At the dose of ED90, the combination of
docetaxel with vemurafenib was almost additive (CI value as 0.90) while the combination
effect of colchicine with vemurafenib has reversed to antagonism (CI value as 1.36).
Compared with docetaxel or colchicine, ABI compounds showed greater synergy when
combined with vemurafenib in the resistant A375RF21 cells. Dose –response curve in
Figure 2-5 also clearly showed that in both A375 parental and vemurafenib-resistant
A375RF21 subline, the combination of ABI-274 with vemurafenib dramatically
increased the anti-proliferation activity comparing with the simple sum of the single
treatment.
2.3.6 Combination of ABI-274 and Vemurafenib Produced Synergistic Cell Cycle
Arrests in A375RF21 Cells
As a tubulin inhibitor binding to the colchicine site, ABI-274 effectively blocks
the G2/M phase in the parent A375 cell line in a dose-dependent manner (129). To
determine whether a combination of ABI-274 and vemurafenib will arrest vemurafenibresistant cells at different replication phases, we carried out cell cycle analysis in
A375RF21 cells. After 24 h exposure to a compound solution at the indicated
concentrations, data in Figure 2-6 clearly indicated synergistic cell cycle arrests. For
DMSO controls, 50% of A375RF21 cells were distributed in G0/G1 phase and the
percentage of cells in S or G2/M phase was 12% or 32%, correspondingly. For ABI-274
single treated group at a concentration of 20 nM, the percentage of cell distributed in
G2/M phase had accumulated up to 70%. Using vemurafenib as a single agent, to produce
similar G0/G1 cell cycle arrest in the resistant A375RF21 cell line, the concentration of
vemurafenib had to be increased to 30 μM or higher, compared with less than 1 μM in the
parental A375 parental cells. As anticipated, the combination of vemurafenib and ABI274 strongly arrested A375RF21 cells in both G0/G1 (48%) and G2/M (43%) phase. In
addition, this combination treatment generated much more cell debris which indicated an
increase in cancer cell apoptosis. Treatment with the combination of vemurafenib and
docetaxel produced similar synergistic effects. Flow cytometry analysis with antiphospho-histone H3 staining (Figure 2-7), which distinguishes the cells between G2 and
M phase, confirmed the same pattern of synergistic cell cycle arrests due to the
combination treatments.
2.3.7 Combination Treatment Induced Significantly Increased Apoptotic and Cell
Death in Vemurafenib-resistant Cells
To understand more clearly the possible cell apoptosis induction effect of the
combination treatment, we utilized Annexin V and Propidium Iodide co-staining flow
cytometry to differentiate live and apoptotic cells in A375RF21. As expected, single
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Figure 2-5. In vitro dose-response curves (n = 5) of each combination in A375 and
A375RF21 cells
X-axis of each plot is the dose density regarding IC50 concentrations of drug A or B on
A375 or A375RF21 cells in an A+B combination treatment. Figure A to C is the data
from A375 cells and Figure D to F is the data from A375RF21 cells.
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Figure 2-6. Cell cycle analysis for combination of ABI-274 with vemurafenib (n =
4)
A, A375 or A375RF21 cells treated with 1 μM vemurafenib for 24 h and compared with
the DMSO control group. Vemurafenib at 1 μM effectively arrested A375 cells at G0/G1
phases but could not arrest resistant A375RF21 cells. B, A375RF21 cells treated with
DMSO, 30 μM vemurafenib, 20 nM ABI-274, 20 nM docetaxel and the combinations for
24h. ABI-274 and docetaxel induced G2/M arrest in A375RF21 cells and their
combinations with vemurafenib arrested cells in G1/G2/M phases.
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Figure 2-7. Anti-phospho-histone H3 and PI (propidium iodide) bivariate staining
cell cycle analysis on vemurafenib-resistant A375RF21 cells
A, representative diagrams illustrated the cell distribution. The red lines were defined
manually to show how the cell cycle phase distribution had been calculated accordingly.
B, quantification data (mean ± S.D.) for cell cycle phases distribution. Ctrl: 5 ‰ DMSO;
Vem: vemurafenib 30 μM; ABI: ABI-274 20 nM; Vem + ABI: vemurafeib 30 μM +
ABI-274 20 nM; Doc: docetaxel 20 nM; Vem + Doc: vemurafeib 30 μM + docetaxel 20
nM.

29

agent treatment produced only moderate effects on inducing cell apoptosis at tested
concentrations; in contrast, the combination treatment groups significantly enhanced the
apoptosis (Figure 2-8A). As shown in Figure 2-8B, in which we quantified the
percentage sum of cell distributed in Q1 (early apoptosis), Q2 (apoptosis) and Q4 (dead
cells), the combination of ABI-274 and vemurafenib resulted in 50 ± 7.6 % of counted
cell apoptosis or death, which is much higher than the simple sum of apoptotic
percentages in two single agent treatment groups (11.8 ± 3.0 % for ABI-274 and 11.9 ±
3.5 % for vemurafenib). A similar synergy effect of apoptosis induction was also
observed in the combination treatment group containing docetaxel (6.4 ± 3.0 % for
docetaxel group, 38.1 ± 2.6 % for combination).
2.3.8 Combination Mitigates Acquired Vemurafenib Resistance by Down-regulating
pAKT or Total AKT and Activating Apoptosis Cascades
It has been established that ABI-274 targets tubulin polymerization (125, 126) and
vemurafenib targets BRAFV600E. As the first approach to understand responsible
molecular mechanisms leading to this strong synergistic combination, we investigated
whether the synergy is mediated through potentiation of the direct target of ABI-274 or
vemurafenib. As shown in Figure 2-9 vemurafenib did not have any effect on tubulin
polymerization, even at a high concentration of 20 μM. The addition of vemurafenib to
ABI-274 at most marginally increased the inhibition of tubulin polymerization compared
with the single agent ABI-274. The inhibition of tubulin polymerization in the
combination treatment was exclusively contributed by ABI-274, suggesting the
synergistic combination was not mediated through potentiation of the direct target
inhibition for ABI-274.
Next we determined using western blotting whether the combination has any
effects on pERK, the hallmark of BRAFV600E inhibition by vemurafenib. Figure 2-10A
revealed that either ABI-274 or the combination treatments had no obvious effect on
pERK or total ERK level after 48h incubation with A375RF21 resistant cells. Replacing
ABI-274 with another tubulin inhibitor, docetaxel, produced similar results in Figure
2-10A). Therefore, the synergistic combination was unlikely through potentiation of the
inhibition of BRAFV600E.
Recently, Fei Su et al reported that pAKT levels were increased in A375
vemurafenib-resistant clones compared with their parental vemurafenib-sensitive cells
(28). Since A375RF21 cells also have strong pAKT activation (Figure 2-10A), we
hypothesize that the combination treatment may produce its strong synergy through
down-regulating activities in the AKT pathway in vemurafenib-resistant A375RF21 cells.
As shown in Figure 2-10A, both pAKT and total AKT (tAKT) were greatly reduced in
single-agent ABI-274 or its combination treatment group after 48h incubation, suggesting
that the synergistic anti-proliferation might be mediated by simultaneously targeting both
ERK and AKT phosphorylation. Docetaxel also reduced the pAKT and tAKT expression
and had similar effects in its combined treatment with vemurafenib. For example, in
addition to the obvious reduction of tAKT levels, the combination of ABI-274 and
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Figure 2-8. Combination of tubulin inhibitors with vemurafenib synergistically
increased proportion of cell apoptosis or death in resistant A375RF21 cells
A, representative quadrant diagrams illustrated the cell distribution in Q1 (early
apoptosis), Q2 (apoptosis), Q3 (live), and Q4 (dead). Cell clusters with high-SSC (side
scatter)/ low-FSC (forward scatter) cyto-morphological profiles were colored in black.
There was no back-gating difference between grey and black populations. B, apoptosis
fraction was calculated by adding distribution percentage in Q1, Q2 and Q4 together.
Drug combinations induced significantly higher (*P < 0.05) portion of apoptosis
compared with simple sum of apoptosis fraction in two single agent treatment groups.
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Figure 2-9. Effect of single agent and combination treatment on purified-protein
based tubulin polymerization assay (n = 3)
Vemurafenib at 20 μM did not significantly influence tubulin polymerization compared
with DMSO control group. The tubulin polymerization inhibition effect in the
combination treated group was solely contributed by ABI-274.
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Figure 2-10. Western blot analysis with indicated antibodies on lysate of
A375RF21 (A), MDA-MB-435 and WM164 cells (B) after 48h treatment while
GAPDH was used as a loading control
A, while the indicated combination treatment only caused moderate decreasing of p-ERK
level, they largely inhibited the AKT phosphorylation and increased the level of apoptotic
markers including cleaved PARP and cleaved caspase-3. B, ABI-274 also displayed AKT
knock-out effects in other two BRAFV600E mutant human melanoma cell lines, MDAMB-435 and WM164.
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vemurafenib reduced the level of pAKT to 61% relative to tAKT (calculated from the
quantified relative folds of lane density: 0.08/0.13×100%) while the single-agent
treatment only reduced the levels of pAKT to 77% (ABI-274, 0.6/0.77×10%) and 70%
(vemurafenib, 0.34/0.48×100%) relative to the corresponding levels of tAKT,
respectively.
The strong dose-dependent pAKT/tAKT inhibition effects of ABI-274 were
further confirmed in other two BRAFV600E mutant cell lines, WM164 and MDA-MB-435
(Figure 2-10B). Furthermore, since the highly phosphorylated AKT level is associated
with upregulated PDGFRβ/PI3K in A375RF21 cells (Figure 2-4A), we continued to
check the changes of PDGFRβ/PI3K levels in response to both single and combination
treatment. Representative results in Figure 2-11 revealed that after 24hr incubation, ABI274 or docetaxel at the concentration of 20nM generally wiped out the PDGFβ and
leaded to the down-regulation of PI3K level in A375RF21 cells. As a result, the AKT
upstream PDGFRβ/PI3K levels were greatly reduced in combination treatment groups,
although vemurafenib single treatment did not significantly affect the PDGFRβ/PI3K.
Therefore, our data indicates that ABI-274 or docetaxel down-regulates pAKT/tAKT
activity through the inhibition of PDGFRβ/PI3K pathway.
In the vemurafenib-resistant cells (Figure 2-10A), decreased cyclin D1 levels in
vemurafenib and the combination treatment groups indicated inhibitions on G0/G1 cellcycle progression. Apoptosis markers, cleaved PARP and caspase-3, were highly induced
by tubulin inhibitors while vemurafenib slightly increased their expression. This result is
consistent with our observation in apoptosis detection experiment.
2.3.9 Combination of Vemurafenib and ABI-274 Synergistically Suppresses
Vemurafenib-resistant Tumor Growth In Vivo
To evaluate whether the strong synergy observed against A375RF21 cells in vitro
could be transferred to vemurafenib-resistant tumors in vivo, we compared the effect of
combination efficacy on tumor growth with single agent treatments. We previously
established that ABI-274 is effective in suppressing parental A375 melanoma tumor
growth in vivo at a dose of 25 mg/kg (129). A pilot study showed that vemurafenibresistant A375RF21 cells had similar growth kinetics to their parental A375 cells in the
absence of drug treatment. We reduced the dose of ABI-274 to 10 mg/kg in the current
study in order to avoid any potentially unexpected toxicity due to its combination with
vemurafenib.
As shown in Figure 2-12 and Table 2-3, vemurafenib (20 mg/kg) mono-therapy
only achieved minimal (22.65%) TGI and ABI-274 (10 mg/kg) by itself resulted in
slightly better TGI at 38.12% in this vemurafenib-resistant tumor model; in contrast, their
combination treatment significantly enhanced tumor inhibition to 88.56% after 3-week
treatment (Figure 2-12A, B and Table 2-3). Three out of the seven mice that received
combination therapy were kept for additional 7 days without further treatment,
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Figure 2-11. Western blotting analysis for cell lysates of A375RF21 incubated with
indicated treatment for 24 h
The densitometry data was measured by ImageJ software and normalized according to
the reading from beta-actin loading control groups.
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Figure 2-12. In vivo combination of vemurafenib and ABI-274 in the resistant
A375RF21 xenograft model (n = 7)
A, pictures of isolated tumor tissue. B, tumor volume growth curve. C, mice body weight
versus time plot. D, representative immunohistochemistry images for H&E, Ki67, pAKT,
pERK and S100 staining of xenograft tumor tissue sections after three weeks of single
agent or combination treatment. The scale bar (yellow or blue) in each image represents
100 μm.
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Table 2-3.
Tumor growth inhibition (TGI) and tumor weight comparison for in
vivo combination of vemurafenib and ABI-274 in the resistant A375RF21 xenograft
model (n = 7)
Treatment group

TGI (%)

Vehicle

-

Tumor weight
(gram)
2.48 ± 0.27

ABI-274 10 mg/kg

38.12 ± 6.14

1.77 ± 0.11

Vemurafenib 20 mg/kg

22.65 ± 8.31

2.05 ± 0.14

88.56 ± 3.57*

0.77 ± 0.17

81.27 ± 5.52*

0.90 ± 0.11

Vemurafenib 20 mg/kg + ABI-274
10mg/kg (after 3 weeks of treatment)
Vemurafenib 20 mg/kg + ABI-274
10mg/kg (additional 7 days without
treatment)

The combination of ABI-274 at 10 mg/kg and vemurafenib at 20 mg/kg achieved greater
antitumor activity (TGI) compared with the simple sum of TGI in two single agent
treatment groups (*P < 0.05). The synergistic tumor inhibition sustained after additional
one week without further treatment (*P < 0.05).
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and showed no significant (P = 0.2857) tumor relapse and maintained 81.27% tumor
suppression. During the entire experiment, no mice in the four groups lost body weight
by more than 10% (Figure 2-12C), indicating the absence of gross toxicity for these
treatments. When mice were euthanized, major organs including brain, hearts, kidney,
liver, spleen, and lungs were isolated and were submitted for pathological analysis. No
abnormalities were observed on these organs. Collectively, these results strongly
indicated that this combination treatment effectively helped overcoming the acquired
resistance to vemurafenib in A375RF21 melanoma model and further confirmed the
synergistic anti-proliferation effects observed in vitro.
To determine whether the down-regulation of AKT signaling by combination
treatment observed in vitro also functions in vivo, we performed immunohistochemistry
analyses on tumor sections from all the experimental groups. We also determined the
activity in the ERK pathway and assessed the proliferation level indicated by cell marker
Ki-67 in tumor sections. As shown in Figure 2-12E, the improved pathway and
proliferation inhibition in the combination treatment groups corresponded well with
overall tumor response TGI results. ERK and AKT phosphorylation together with Ki67
expression levels in either nucleus or cytoplasm were largely reduced in the combination
treatment group. Furthermore, wide area of background pink colored from Matrigel in
H&E staining for tumor sections in the combination treatment group indicated that very
few tumor cells, if any, remained after combination treatment. The significant reduction
of melanoma cells in the combination treatment group was further confirmed by the
reduced density in S100 immunostains (Figure 2-12D).
Since the results presented in Figure 2-12 and Table 2-3 were promising but did
not seem to result in tumor regression, we repeated the experiment by increasing the dose
by 50% for both ABI-274 and vemurafenib. The results are shown in Figure 2-13 and
Table 2-4. There is a slight increase of efficacy for vemurafenib (TGI of 22.65% at 20
mg/kg vs. 28.10 % at 30 mg/kg), and there is substantial increase of efficacy for ABI-274
(TGI of 38.12% at 10 mg/kg vs. 72.72 % at 15 mg/kg). Moderate tumor regression (44.9
%) on the combination treatment group with the increase drug dose was apparent as
shown in Figure 2-13B. Collectively, these data provided the first convincing evidence
that the combinations of novel tubulin inhibitors, such as ABI-274 with vemurafenib, are
likely to overcome the acquired resistance to vemurafenib for melanoma patients having
BRAFV600E mutation.
2.3.10 Establishment of Vemurafenib-resistant MDA-MB-435 VemR Melanoma
Subline
To further expand the panel of vemurafenib-resistant cell model that can be used
to evaluate the efficacy and mechanism of our combination treatment, we chronically
selected one additional melanoma cell line with acquired resistance to vemurafenib,
MDA-MB-435 VemR cells, following similar procedure that we used to generate
A375RF21 cell line.
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Figure 2-13. In vivo combination of high dose vemurafenib (30 mg/kg) and ABI274 (15 mg/kg) in the A375RF21 xenograft model (n = 5)
A, pictures of isolated tumor tissue. B, tumor volume growth curve. C, mice body weight
versus time plot. Combination of ABI-274 and vemurafenib at this dose achieved about
45% of tumor regression.
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Table 2-4.
Tumor growth inhibition (TGI) and tumor weight comparison for in
vivo combination of vemurafenib (30 mg/kg) and ABI-274 (15 mg/kg) in the resistant
A375RF21 xenograft model (n = 5)
Treatment group

TGI (%)

Tumor weight
(gram)

-

1.60 ± 0.22

Vemurafenib 30 mg/kg

28.10 ± 4.81

1.05 ± 0.21

ABI-274 15 mg/kg

72.72 ± 8.29

0.51 ± 0.12

103.38 ± 1.42

0.08 ± 0.03

Vehicle

Vemurafenib 30 mg/kg + ABI-274
15 mg/kg
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As determined by MTS assay, the established MDA-MB-435 VemR subline is
resistant to both vemurafenib and another recently approved BRAF inhibitor, dabrafenib.
IC50 of vemurafenib increased over 14 folds, from 678 ± 24 nM in MDA-MB-435 cells to
9.82 ± 0.04 μM in MDA-MB-435 VemR cells. And IC50 of dabrafenib increased over 50
folds, from 4 ± 1 nM in MDA-MB-435 cells to 211 ± 13 nM in MDA-MB-435 VemR
cells. However, as shown in Figure 2-14A, MDA-MB-435 VemR cell was not crossresistant to MEK inhibitors trametinib. This phenotype indicated that MDA-MB-435
VemR had developed resistance to BRAF inhibitor through mechanism different from
A375RF21 cells. In fact, western blotting analysis (Figure 2-14B) revealed that PDGFRβ
level in MDA-MB-435 VemR cells was largely decreased comparing with that in MDAMB-435 parental cells, which is distinct from A375RF21 cells. Interestingly, although no
significant activation of AKT/mTOR was observed in MDA-MB-435 VemR cells, MEK
phosphorylation level maintained in the resistant cells when it was treated by
vemurafenib. Therefore, MDA-MB-435 VemR adopted the resistance to BRAF inhibitor
through MEK activation mediated mechanism.
2.3.11 Combination of Tubulin Inhibitor with BRAF Inhibitor Showed Synergistic
Anti-proliferation Effects in Expanded Panel of Vemurafenib or Trametinib
Resistant Cell Lines
Due to the complexity of BRAF inhibition resistant mechanism and the
heterogeneity of melanoma tumor, the efficacy of combination therapy need to be tested
on expanded panel of BRAF resistant cell lines other than A375RF21. In our antiproliferation study, combination of tubulin inhibitor with BRAF inhibitor continuously
displayed synergistic effect in MDA-MB-435 VemR, 451LuMR and WM983B BR cells.
Among them, 451LuMR and WM983B BR cells were established by Dr. Mennhard
Herlyn’s lab through chronical exposing BRAFV600E human melanoma 451Lu and
WM983B cells to trametinib or vemurafenib, accordingly. These cells are found to cross
resistant to vemurafenib, dabrafenib and trametinib(131). Combination index as shown in
Table 2-5 indicated that ABI-274 combined with either vemurafenib or dabrafenib
displayed strong in vitro synergistic effect in MDA-MB-435 VemR cells. In 451LuMR
and WM983B BR cells, combination therapy of ABI-274 and vemurafenib showed
sustained synergistic growth inhibition, while the combination of vemurafenib with
trametinib only had additive anti-proliferation activity.
2.4 Discussion
Although vemurafenib, the first drug approved for melanoma patients harboring
BRAFV600E mutation, showed remarkable responses in initial therapy, almost all patients
taking this drug developed resistance to vemurafenib within a few months (132).
Understanding the underlying mechanisms of either primary or acquired resistance and
developing suitable combination strategies could provide more effective ways to
overcome such resistance. There is a rich literature in both preclinical studies and clinical
trials to search for effective combination of vemurafenib with other agents in order to
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Figure 2-14. Establishment of BRAF inhibitor resistant MDA-MB-435 VemR
subline with chronically selection in vitro
A, dose-growth inhibition curves of MDA-MB-435 VemR cells when treated by BRAF
inhibitor, MEK inhibitor or tubulin inhibitor. Data was determined by MTS assay in vitro
(n = 4). B, western blotting analysis revealed that MDA-MB-435 developed resistance to
BRAF inhibitors through MEK activation mediated mechanism.
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Table 2-5.
Combination of BRAF inhibitors with ABI-274 showed synergistic
effect in the expanded panel of vemurafenib-resistant melanoma cell lines
Cell line
MDA-MB435 VemR

BRAF
inhibitor
Vemurafenib

Dabrafenib

451LuMR

WM983B
BR

Vemurafenib

Vemurafenib

Tubulin
inhibitor
ABI-274

CI at ED50

CI at ED75

CI at ED90

0.59

0.55

0.52

Docetaxel

0.55

0.94

1.03

Vinblastine

0.79

0.95

1.13

ABI-274

0.37

0.43

0.51

Docetaxel

0.84

0.84

0.85

Vinblastine

0.44

0.44

0.47

ABI-274

0.96

0.74

0.68

Docetaxel

0.44

0.60

0.82

Trametinib

0.73

1.15

1.03

ABI-274

0.29

0.39

0.74

Docetaxel

0.24

0.49

1.04

Trametinib

2.03

1.26

0.94

The combination index (CI) values were calculated based on the results from cell
viability MTS assay (n = 5). CI < 0.9 indicates synergism; 0.9 ≤ CI ≤ 1.1 indicates
additive effect; CI > 1.1 indicates antagonism between the two tested drugs.
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eliminate or reduce melanoma tumor resistances to BRAF or MEK1/2 inhibitors (28, 37,
39, 80, 124, 133, 134). Inhibitors to the RAF/MEK/ERK pathway mainly produce G1
cell-cycle arrest rather than melanoma tumor cell death. Thus a combination of agents
targeting different components in the same pathway (e.g. combination of vemurafenib
and MEK1/2 inhibitors), while effective initially (109), may not maintain long-lasting
synergy against resistant cells that can escape from these G1 cell-cycle arrests.
Activation of the PI3K/AKT/mTOR signaling pathway has been shown to
contribute to the diminished sensitivity to ERK1/2 inhibition in human melanoma cell
lines (135), and several recent studies have clearly demonstrated the synergistic
combination of an inhibitor targeting PI3K/AKT/mTOR pathway and a BRAF inhibitor
or a MEK inhibitor (35, 39, 135, 136). Recently several novel classes of compounds were
reported as inhibitors of tubulin polymerization and also showed strong inhibition of the
AKT pathway (137-139). In addition, constitutively active PI3K/AKT pathway has been
shown to lead to multidrug resistances to microtubule-targeted tubulin-polymerizing
agents (MTPA) and inhibition of PI3K/AKT-mediated signaling pathway has been shown
to sensitize cancer cells to MTPA-induced apoptosis (140). These studies indicate a close
interplay between tubulin polymerization inhibitors and AKT down regulation in cancer
cells. In addition, Nikolas K.H et al. has recently reported that MEK inhibitor AZD6244
induced growth arrest in melanoma cells and tumor regression when combined with
docetaxel (141). Interestingly, our current report is consistent with these studies. The in
vivo studies presented here show an effective combination treatment in tumor cells that
are already vemurafenib-resistant by using A375RF21 xenograft models. It is
conceivable that if we used the combination before tumor cells became resistant to
vemurafenib, tumor regression may be more enhanced and we could significantly delay
or even prevent the development of resistant tumor cells. This could translate into at least
a substantially longer progression-free time in patients, and/or enhanced disease
regression. Collectively, our study offers the first direct evidence and a rationale for
combining a potent tubulin inhibitor with an inhibitor targeting the RAF/MEK/ERK
pathway for greatly improved therapy for melanoma patients.
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CHAPTER 3.

LITERATURE REVIEW OF SURVIVIN AND ITS
ANTAGONISTS

3.1 The Structure and Tissue Distribution of Survivin
Survivin (encoded by BIRC5), the smallest member of the inhibitor of apoptosis
proteins (IAPs), is a 16.5kDa protein that consists of an N-terminal Zn2+-binding
baculoviral inhibitor-of-apoptosis (IAP) repeat (BIR) domain and an amphipathic Cterminal helix (142-144). Two molecules of human survivin form a homodimer through a
hydrophobic interface, which locates in a region between the BIR domain and C-terminal
alpha helix (145).
Survivin is ubiquitously expressed in lung, breast, gastric, bladder, colon and
prostate cancer, lymphoma, esophageal carcinoma and osteosarcoma cells but
undetectable in finally differentiated adult normal tissues (146-149). And its tumor
specific distribution pattern in human tissues has distinguished survivin from other
members in IAP family (150, 151). Overexpression of survivin is positively correlated
with tumor invasion, multiple drug resistance, and unfavorable prognosis with decreased
patient survival rates (150, 152-156). Recent studies also revealed that there is a definite
correlation between high levels of survivin and the over-activation of known oncogenic
pathways (HIF-1α (157), HSP90 (158, 159) PI3K/AKT (160, 161), ERK (162), Bcl-2
(14,15) and RAS pathways(163, 164)), but negatively correlate with tumor suppressor
genes(165-167) (p53, PTEN). In addition, the presences of survivin in physiological
fluids including urine, bronchial aspirate, pleural effusion and plasma make survivin as a
useful biomarker to non-invasively monitor tumor relapse and metastasis(168, 169).
3.2 The Expression and Regulation of Survivin
Survivin expression dominantly peak in the G2/M phase, followed by a rapid
degradation via the ubiquitin-proteasome pathway during G1 phase (161, 170). Studies
have shown that this cell-cycle dependent pattern results from the reduced degradation of
survivin rather than the up-regulated gene transcription in G2/M phase (171). The halflife of survivin is as short as 30 min and its degradation is considered to be involved with
the X-linked inhibitor of apoptosis (XIAP) – associated factor 1 (XAF1). The XAF1XIAP interaction activates the ubiquitin ligase activity of XIAP and thus degrades
survivin (172). Meanwhile, heat shock protein 90 (Hsp90), one of the most important
molecular chaperones in mammalian cells, binds to survivin BIR domain through ATPase
domain of Hsp90 and protect survivin from the ubiquitin-mediated degradation (Figure
3-1)(158).
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Figure 3-1.

The nodal functions of survivin and targets of survivin inhibitors
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3.2.1 Control of Survivin Gene Expression by Transcription Factors
Multiple upstream factors control the gene expression of survivin, including but
not limiting to tumor suppressor p53, specificity protein 1 (Sp1), and Forkhead box O3
(FOXO3).
The interplay between p53 and survivin is mutual. In one hand, p53 can direct
bind to and stimulate the DNA methyl-transferase (DNMT) 1(173), which methylates
survivin promoter and leads to survivin gene repression. On the other hand, ectopic
survivin decreases the mRNA level of p53 and Mdm2 in Adriamycin-treated MCF7 cells
(174). In many cases, loss of wild-type p53 and survivin overexpression co-exist in
cancer with elevated resistance to therapy. Also p53 gene mutant status is found to be
highly associated with the expression of survivin and its anti-apoptotic splice variants,
survivin-deltaEx3 and survivin-3B, in 163 breast carcinoma tissues (175).
Chen et al (176) has shown that Sp1 can cooperate with Sp3 to regulate the basal
expression level of survivin in Hela cells. Sp1 directly bind to the TATA-less regions of
survivin promoter through the interaction with two Sp1 binding sites on that promoter
(position -148 to -153; position -127 to -140). Furthermore, Sp1 is co-overexpressed with
survivin in adenocarcinoma of lung cells A549 (177). In this model, Sp1 up-regulates
survivin expression through direct binding with survivin promoter and lead to the
deduction of caspase-9 activity (177).
FOXO3 increases in cell response to high level of intracellular reactive oxygen
species (ROS). The nuclear translocation of FOXO3 and activation of FOXO3/FKHRL1
represses the survivin transcription in human neuroblastoma (NB) tumor and sensitize it
to doxorubicin treatment (178). In fact, survivin induces mitochondria fragment, reduces
mitochondrial respiration and thus protects NB cells from the FOXO3-mediated
mitochondrial apoptosis (179).
Other nuclear factors like kappa-light-chain-enhancer of activated B cells (NFκB) (180), signal transducer and activator of transcription-3 (STAT3) (181), Winglesstype MTV integration site family member (Wnt) (182) have been reported to increase the
mRNA level of survivin. And insulin-like growth factor (IGF) can promote the
translation of survivin and prostate cancer cell survival through activating
phosphoinositide 3-kinase (PI3K)/ AKT/ mammalian target of rapamycin (mTOR)
signaling pathway (183).
3.2.2 Post-translational Modification of Survivin
Besides the mRNA-level regulation of survivin, post-translational modification
determines the survivin function and its distribution among nuclear, cytoplasm and
mitochondria. Generally, two major types of post-translational modification survivin are
reported in the literature: phosphorylation and acetylation (Figure 3-1).
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Survivin can be phosphorylated at several sites that shape its molecular functions,
including Thr34, 53 and 117 plus Ser20. Thr34 of survivin is phosphorylated by cyclin
dependent kinase (CDK)/p34cdc2-cyclcin B1 and this process results in “activated”
survivin that is able to bind with caspase-9 in Hela cells (184). Ser20 of survivin can be
phosphorylated by protein kinase A (PKA) or polo-like kinase 1 (PLK1) but evidences
exist that they contribute to different molecular function of survivin. The phosphorylation
of survivin through PKA-mediated mechanism specifically occurs in cytosol rather than
mitochondria and leads to the stabilization of XIAP and subsequently anti-apoptosis
effect (185). Interestingly, in cytosol PLK1-mediated phosphorylation of survivin at
Ser20 is discovered to activate Aurora B and promote the formation of chromosomal
passenger complex (CPC) in nucleus. In this way, PLK1 regulates cell mitosis (186).
Next, the acetylation of survivin at residue Lys129 is regulated by factors like
CREB binding protein (CBP) and histone deacetylase 6 (HDAC6). CBP directly
acetylates survivin and catalyzes its homo-dimerization and accumulation in nucleus.
Subsequently, the acetylated survivin binds to the N-terminal of STAT3 and decreases
STAT3 oncogene activity (187). HDAC6 de-acetylates survivin and promotes the nuclear
export of survivin in MCF7 breast cancer cells (188).
3.3 The Nodal Functions of Survivin
Functionally, nuclear survivin is a component of CPC (189), which regulates
chromosomal segregation during cell division (190). Cytoplasmic and mitochondrial
survivin inhibits the cell apoptosis both directly and indirectly through caspases-mediated
mechanisms (Figure 3-1) (150, 154, 155).
3.3.1 Apoptosis
Survivin interferes the apoptosis process in both caspases-dependent and
caspases-independent mechanisms. As indicated above, Thr34 phosphorylated survivin in
mitochondria can bind directly with caspase-9 and thus prevent caspase-9 activation.
Also the formation of survivin-XIAP complex protects ubiquitin-mediated degradation of
XIAP and thus indirectly inhibits caspase-9 activation (172). Interestingly, survivin is
found to bind with caspase-3 and caspase-7 with high affinity in vitro under cell-free
condition (191). Meanwhile, the anti-apoptotic effect of survivin relies on the direct
interaction between survivin and a mitochondria protein, Smac/DIABLO (second
mitochondria-derived activator of caspases). In this case, survivin sequesters
Smac/DIABLO away from XIAP binding and inhibits Smac/DIABLO releasing from
mitochondria (144, 192, 193). Structure analysis showed that Smac/DIAOBLO
competitively binds with survivin BIR domain through N-terminal Ala-Val-Pro-Ile
(AVPI) tetra-peptide motif like it does with other IAP proteins (144, 194). Additionally,
survivin induces the translocation of mitochondrial apoptosis-inducing-factor (AIF) from
cytoplasm to nucleus and promote caspase-independent pathway with DNAfragmentation (195).
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3.3.2 Mitotic
CPC consists of two distinct units: an enzymatic complex contains Aurora B and
C-terminal fragment of the inner centromere protein (INCENP), and a chromosomal
localization complex contains N-terminal fragment of INCENP, survivin and Borealin
(196). BIR domain of survivin interacts with phosphorylated Thr3 on histone H3
(H3T3ph) through N-terminal Ala1 (194) and activates the kinase function of Aurora B
(197). The formation of CPC and recognition of survivin BIR domain with Aurora B are
crucial for both the proper chromosomal alignment and mitotic spindle assembling (189).
3.3.3 DNA Repair and Autophagy
The mechanism of survivin interfering with DNA-repair and autophagy has not
been studied as clear as its function involves apoptosis and cell division. Current
evidences show that nucleus survivin interacts with or regulates the level of various
DNA-damage/repair-associated modules like Ku70 (a DNA-damage molecular sensor)
(198) and DNA-dependent protein kinase catalytic subunit (DNA-PKCs) (199). Silencing
survivin may induce autophagy-dependent apoptosis in hepatocellular carcinoma cells
(200). And the down-regulation of survivin through knock-out of Beclin 1, an important
autophagy regulator, sensitizes glioma cells to TRAIL-induced apoptosis (201).
3.4 Current Antagonists of Survivin as Anti-tumor Agents
3.4.1 Small Molecule Inhibitors
Survivin is not enzymatic protein and doesn’t occupy common “druggable”
binding site on its surface. Therefore, it makes the discovery of small molecule survivin
antagonist fairly difficult. Generally, small molecule agents under current development
antagonize survivin function in three distinct mechanisms.
The first category is survivin expression modulator, which blocks either survivin
gene promoter or transcriptional factor. For example, YM155, which is under Phase II
clinical investigation, selectively suppresses the gene expression of survivin over the
other IAPs and induces caspase or autophagy-mediated apoptosis in various cancer type
(202-206). In xenograft models, YM155 can lead to tumor regression and sensitize the
tumor to the treatment of commonly used chemotherapy agents (206, 207). Another
example is FL118, which binds to survivin gene promoter region at low nano-molar
concentration in a p53-independent manner and shows great anti-tumor efficacy in
xenograft models (208, 209). Terameprocol (EM1421) inhibits Sp1 and subsequently
reduces transcription of survivin, CDK1 and VEGF(210). Its administration as vaginal
ointment is well tolerated in PhaseI/II trials in women with HPV-linked cervical
squamous intraepithelial neoplasia but limited systemic absorption (211). However, in a
more recent Phase I study, where terameprocol is co-currently administered with enzyme-
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inducing antiseizure drugs (EIASDs) intravenously for 5 consecutive days each month in
high-grade glioma, the combination therapy is well tolerated without alteration of
terameprocol pharmacokinetic profile and myelosuppression side effects (212).
The second type of small molecule survivin inhibitor interferes with the
interaction between survivin and other proteins like Hsp90 and Smac/DIABLO. A
peptidomimetic of survivin sequence K79 to L87, shepherdin, can bind to ATP pocket on
Hsp90 N-terminus and then destabilize survivin together with other Hsp90 client proteins
like AKT, CDK6 and telomerase (213, 214). Shepherdin induces both apoptotic and nonapoptotic massive cancer cell death and is well tolerated in mice model. The non-peptidic
5-aminoimidazole-4-carboxamide-1-b-D-ribofuranoside (AICAR) directly binds to
chaperone through hydrogen bonds between ribose ring of AICAR and Asp93 of Hsp90
protein. And it destabilizes survivin and exerts anti-cancer activity through mechanisms
similar to shepherdin (215). Oikawa et al. has reported the identification of a 5-dezaflavin
analog that selectively inhibits the interaction of survivin-Smac/DIABLO but not
survivin-INCENP through high through-put system. This compound sensitizes the lung
carcinoma A549 cells to doxorubicin-induced DNA damage and synergistically enhances
the apoptotic cell death (193).
Some other small molecule survivin inhibitors regulate the post-translational
modification of survivin mainly through the inhibition of CDK-mediated phosphorylation
of survivin Thr34. Reported compounds in this category include flavopiridol (216),
NU6140(217) and purvalanol A (218, 219). But usually their anti-cancer effect is not
solely based on the inhibition of survivin phosphorylation. Among them, flavopiridol, as
a flavonoid alkaloid pan-CDK inhibitor and the first CDK inhibitor to enter the clinic was
approved as an orphan drug for treatment of chronic lymphocytic leukemia and is
currently undergoing phase II studies as monotherapy and also as in combination regimes
with traditional chemotherapy agents (220, 221).
3.4.2 Survivin Antisense Oligonucleotides (ASOs)
ASOs are developed as to specifically hybridize with complimentary survivin
mRNA and lead to destruction of survivin mRNA by RNAse H (222). Gataparsen (or
LY2181308) is the most advanced survivin ASO and it has an 18-mer 2’-Omethoxyethyl-(MOE) modified structure, which protects it from the nuclease
degradation. Upon binding to translational initiation condo of survivin, gataparsen
activates caspase-3 apoptosis cascade in tumor cells without affecting other proteins and
it is in Phase II clinical study. The maximum tolerable dose of gataparsen is determined
as 750 mg in patients with various solid malignancies and its accumulation in tumor
tissue and survivin-deregulation effect is confirmed in a Phase I study (223). However,
data revealed from a Phase II study in patients with castration-resistant prostate cancer
(CRPC) shows that the combination therapy using gataparsen together with standard
treatment docetaxel/prednisone doesn’t achieve better efficacy compared to a control
group receiving only standard docetaxel/prednisone (224).
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Another survivin ASO under development is SPC3042 (or EZN-3042), which is a
16-mer locked nucleic acid ASO that binds to exon 4 of the survivin transcript (225). In
lung carcinoma A549 and Calu-6 xenograft models, SPC3042 induces 60% downregulation of survivin mRNA and 37-45% tumor growth inhibition (TGI) as single
treatment and 83% TGI as combination treatment with paclitaxel (226). However, recent
data from a Phase I study has reported dose-limiting grade 3 toxicity of SPC3042 as
single treatment in children with relapsed acute lymphoblastic leukemia (ALL), although
2 out of 5 patients are detected with decreased survivin expression. And the study was
terminated due to the severe side effect without further clinical development (227).
3.4.3 Dominant Negative Survivin (DNS)
DNS is a single amino acid mutant form of survivin protein. DNS is designed to
form heterodimer with wild-type survivin and then interfere with the survivin biological
function. Study has shown that delivering DNS plasmid DNA or DNS protein into cancer
cell in vitro or tumor tissue in vivo can induce wide-spread apoptosis and tumor growth
inhibition. One of the well-studied DNSs is the T34A survivin, of which Thr34 is
replaced with alanine. T34A DNS is also referred as “phosphorylation-dead mutation
survivin”, since the phosphorylation of survivin by CDK/p34cdc2-cyclcin B1 on Thr34 is
critical for its stability and anti-apoptotic function. T34A survivin triggers mitochondria
apoptosis pathway, promotes p53-associated apoptosis and enhances the anti-cancer
efficacy of chemotherapy agents like cisplatin and doxorubicin (228). Transfection of
T34A survivin plasmid into YUSAC2 melanoma cells prevented tumor formation upon
s.c. injection in mice model and induction of T34A in established melanoma tumors leads
to 60-70% tumor growth inhibition (229). Fusing an HIV-derived TAT peptide sequence
into T34A survivin greatly increases the cell permeability and protein transduction
efficiency. The TAT-T34A survivin enters YUSAC2 or WM793 melanoma cells within
30 min and leads to caspase-3 activation and cell detachment. Intraperitoneal (i.p.)
injection of TAT-T34A survivin results in rapid tumor accumulation in 1 hr with
induction of apoptosis and aberrant nuclei formation (230).
Besides, the replacement of Cys84 on wild-type survivin with alanine generates
C84A survivin and disrupts the zinc chelating of BIR domain on survivin then abolishes
the anti-apoptosis effect of survivin protein. When C84A survivin coded plasmid is intratumorally injected together with a costimulatory of T cells, B7-1, mouse EL-4 thymic
lymphoma tumor growth has been significantly inhibited. And the combination treatment
generates higher antitumor cytotoxic T-lymphocyte (CTL) activity comparing with the
single treatment groups (231). When survivin C84A mutant is fused with a 9 N-terminal
arginine residues (R9, cell-permeable peptide carrier), the formed SurR9-C84A protein
shows dual actions. In normal cells, it protects differentiated SK-N-SH human
neuroblastoma cells from activated T-cell neurotoxicity (232) and increases the
proliferation of differentiated SK-N-SH and HCN-2 neurons (233). In cancerous cells, it
sensitizes prostate cancer cells to TNF-α and induces tumor-specific intrinsic and
extrinsic apoptosis in colon cancer cells (234). Interestingly, researchers have studied that
the adenovirus transduction of double point mutant survivin (TC34,84AA) into
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hepatocellular cancer cells exerts stronger cytotoxicity effect and this form of survivin
mutant is more sensitive to the ubiquitin-mediated degradation (235).
3.5 Conclusion
Despite extensive efforts since the discovery of survivin in 1997, only a few
survivin antagonists are available for clinical test. Given the fact that survivin is
preferentially distributed in cancer cells rather than normal tissues, survivin antagonists
usually are well-tolerated and inherently show low toxicities (153, 155, 202). However,
inadequate anti-tumor efficacy leads to the major failure in clinical trials of survivin
antagonists. Two categories of factors contribute to the observed efficacy limits. On one
hand, the degradation and unspecific delivery of biological agents include antisense
oligonucleotides (e.g., LY2181308 and SPC3042) (225, 236, 237), ribozymes (29, 30)
and small interfering RNAs (238, 239) restricted their internalization into tumor cells. On
the other hand, the high degree of co-overexpression of survivin with drug-resistant
markers like ABC transporter proteins hindered the efficacy of some survivin antagonists
(153, 240). For example, the tumor cell uptake of YM155, the most potent survivin gene
promoter inhibitor (203, 205, 207), is impeded by P-glycoprotein (Pgp) drug efflux pump
(241), which is practically co-overexpressed with survivin in drug-resistant breast cancer,
renal cell carcinoma and acute myeloid leukemia patients (242-244). Therefore, the
development of new survivin inhibitors that can effectively overcome multidrug
resistance with good pharmacokinetic properties is highly needed.
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CHAPTER 4.

DISCOVERY OF NOVEL SMAC MIMETIC AS SELECTIVE
SURVIVIN INHIBITOR*
4.1 Introduction

The family of inhibitor of apoptosis proteins (IAP) bind to caspases, block the
assembling of pro-apoptotic protein signaling complexes, and thereby prevent the
activation of caspase proteolytic cleavages and the subsequent triggering of apoptosis.
There are eight IAP proteins identified in human: NAIP, cIAP1, cIAP2, XIAP, ML-IAP,
ILP2, survivin, and apollon (172, 245, 246). As overexpression of IAPs frequently occurs
in cancer cells and has been linked to tumor progression, treatment failure, and poor
prognosis, IAPs are considered to be promising therapeutic targets in either directly
eliciting cell death or lowering the threshold for cell death induction of current anticancer
therapeutics (245, 247, 248).
Smac/DIABLO (second mitochondria-derived activator of caspase/direct IAP
binding protein with low pI) molecules released from mitochondria antagonize the IAPs
and can protect caspases from IAP inhibition (245, 247-250). Smac interacts with IAPs
mainly via its N-terminal AVPI binding motif. A proven strategy for inhibiting IAPs is to
disrupt the interaction between an IAP and Smac by developing Smac mimetics (249).
Smac-mimicking IAP antagonists can induce apoptosis in tumor cells and effectively
inhibit tumor growth in mice (251-256). They can also inactivate nuclear factor κB (NFκB) and produce secretion of tumor necrosis factor α (TNF-α) (248, 255). Several Smac
mimetics have entered late stage preclinical development or human clinical testing as
novel cancer therapeutics (251-256). For example, Birinapant (TL32711), now in Phase
II study, can effectively suppress cIAP1 and XIAP at well-tolerated doses and promises
antitumor activity either as a single agent or in combination with standard-of-care
chemotherapeutic drugs in adult patients with advanced solid tumors or lymphoma(257).
However, no IAP inhibitors have been approved by the FDA as of today, and there are
limitations with many existing IAP inhibitors. For example, YM155 is a well-known
survivin inhibitor that has gone through clinical trials, but it has been shown to be a
substrate for the P-glycoprotein (Pgp) drug efflux pump (241), suggesting that it could
suffer from multidrug resistance (MDR) in its eventual clinical use. Thus, exploring
novel scaffolds to develop potent and selective IAP antagonists is still much needed.
Since all IAP proteins share the signature baculoviral IAP repeat (BIR) domain (245),
which interacts with Smac, shape-based virtual screening will be helpful in identifying
potential small-molecule Smac mimetics for regulating apoptosis in cancer cells.
In this chapter, we describe our efforts to identify novel small-molecule Smac
mimetics through an integrated virtual screening and biological validation approach.
* Modified with permission. Wang J, Li W. Discovery of novel second mitochondriaderived activator of caspase mimetics as selective inhibitor of apoptosis protein
inhibitors. J Pharmacol Exp Ther. 2014;349: 319-329.
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Their efficiency in inhibiting IAPs, especially XIAP and survivin (BIRC5), and inducing
apoptosis in cancer cells was further validated in serial biological studies both in vitro
and in vivo. These compounds represent novel scaffolds for IAP inhibition and can be
further optimized to serve as a potential targeted agent for various types of cancers.
4.2 Methods
4.2.1 Shape-based Virtual Screening
The University of Cincinnati’s Drug Discovery Center (UC DDC) Library
(contains 362,910 compounds) was used to conduct the shape-based virtual screening.
All structures were first prepared using the LigPrep module in Maestro Suite 2012
(Schrodinger, LLC, New York, NY) to generate conformers and charged states. We used
the phase_shape program in Canvas (version1.4, Schrodinger, LLC, New York, NY).
Conformers with a shape similarity below 0.7 were filtered out, and hits with a similarity
value above this threshold were selected for subsequent molecular docking process.
4.2.2 Molecule Docking
Crystal structures of Smac bound to XIAP BIR3 domain (PDB ID: 1G73 (249)
and 1TW6 (258)) were processed with the Protein Preparation Wizard, and the grid of
AVPI binding site was defined by Glide (version 5.7, Schrodinger, LLC, New York,
NY). 1000 hits with top-ranked similarity value were docked into the AVPI binding site
in each separate complex. The best docking complexes were subject to restricted
molecular dynamics to release any strains by using the Macromodel module with OPLS2005 force field. The ligand and its surrounding residues within 15 Å were allowed to
move freely, while residues outside the 15-Å radius were kept rigid.
4.2.3 Cell Culture and Reagents
Human melanoma A375 cell line and human prostate PC-3 and DU145 cell lines
were acquired from American Type Culture Collection (Manassas, VA). Human
melanoma M14 cell line was kindly provided by Dr. Robert Clarke (Georgetown
University, Washington, DC). Human keratinocyte Hacat cell line was a gift from Dr.
Andrzej T. Slominski (University of Tennessee Health Science Center, Memphis, TN).
Human dermal fibroblast adult cells (HDFa) cells were purchased from Life
Technologies (Thermo Fisher Scientific Inc., Waltham, MA). All cell lines were
authenticated prior to use for this study. Cancer cells were cultured in DMEM (for
melanoma cells) or RPMI 1640 (for prostate cancer cells) medium (Mediatech, Inc.,
Manassas, VA), supplemented by 10% fetal bovine serum (FBS, Atlanta Biologicals,
Lawrenceville, GA), 1% antibiotic/antimycotic mixture (Sigma-Aldrich, St. Louis, MO)
and 5 μg/mL bovine insulin (Sigma-Aldrich, St. Louis, MO). Hacat cells were cultured in
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10% FBS supplemented DMEM medium. HDFa cells were maintained in supplemented
Gibco® Medium 106 (M-106-500, Life Technologies). Compounds were dissolved in
dimethyl sulfoxide (DMSO, Sigma-Aldrich, and St. Louis, MO) to make a stock solution
of 10 mM. Compound solutions were freshly prepared by diluting stocks with cell culture
medium before use (final solution contained less than 0.5% DMSO). Proteasome
inhibitor MG-132 was purchased from Enzo Life Sciences, Inc. (Farmingdale, NY).
4.2.4 Cell Viability Assay
Resources of cell line and culture reagent can be found in Supplemental
Information Method. The anti-proliferation effect against cancer cells of all UC
compounds was first screened in vitro by using the MTS assay as described previously
(127, 129, 259). Then the IC50 values of selected hits were tested through the
sulforhodamine B (SRB) assay as reported before (129).
4.2.5 siRNA Silencing Survivin or XIAP Expression
SignalsSilence® survivin or XIAP siRNA and fluorescein conjugated control
siRNA were purchased from Cell Signaling Technology, Inc. (#6351, #6446, #6201,
Danvers, MA). They were transfected into pre-seeded A375 or PC-3 cells by mixing with
Lipofectamin® RNAiMAX reagent (Invitrogen, Thermo Fisher Scientific Inc., Waltham,
MA) at the final concentration of 100 nM in serum-free medium. 24 hr after the
transfection, cells were treated with compound solution to determine the changes of cell
viability.
4.2.6 Caspase Functional Assay
The caspase activity of cancer cells treated by DMSO control or compound
solution after 24-h or 48-h incubation was analyzed using Caspase-Glo® 3/7 and CaspaseGlo® 9 assay kits from Promega Corporation (Madison, WI) as per manufacturer’s
instructions. The readings of relative luminescence unit (RLU) were normalized by the
cell viability results from the same well determined by compatible CytoTox-FlourTM
Cytotoxicity assay kit (Promega, Madison, WI).
4.2.7 Western Blotting
After treatment for the indicated time, A375, PC-3, and DU145 cells were lysed
to determine by Western blotting the relevant IAP family protein levels. Primary rabbit
antibodies were purchased from Cell Signaling Technology, Inc. (Danvers, MA): anticIAP1 (#7065), anti-cIAP2 (#3130), anti-survivin (#2808), anti-XIAP (#2045), anti-livin
(#2978), or anti-GAPDH (#3683). Then anti-rabbit IgG HRP-conjugated secondary
antibody (Cell Signaling, #7071) was used to detect the target protein level Lane
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intensities were quantified with ImageJ software (US National Institutes of Health,
Bethesda, MD).
4.2.8 Flow Cytometry Analysis
Flow cytometry analysis was performed as described previously (129). Briefly,
A375 cells (n = 3) were synchronized through 24 h starvation in growth media containing
only 0.1% FBS. Then the cells were treated with 0, 1, or 4 μM UC-112 in full growth
media (10% FBS) for another 24 h. Then the cell-phase distribution was determined on a
BD LSR-II cytometer (BD Biosciences, San Jose, CA) with 10,000 cells scored, and data
were processed using Modfit 2.0 program (Verity Software House, Topsham, ME).
4.2.9 Human Melanoma A375 Tumor Xenograft Model and Treatment
We first estimated the acute maximum tolerable dose (MTD) for compound UC112. Progressively increasing injection doses via intra-peritoneal (i.p.) injection route to
BXD mice (n = 3) determined the estimated MTD to be above 200 mg/kg with one-week
continuous treatment. To ensure a large safety margin during the three-week treatment
and considering the practical doses in clinical, we scaled down the dose to 20 mg/kg and
40 mg/kg in the xenograft model study.
Seven- to 8-week-old male nude mice were purchased from Charles River
Laboratories International, Inc. (Wilmington, MA). Right before use, A375 cells were
suspended in ice-cold phenol red-free and FBS-free DMEM medium and mixed with
high concentration Matrigel (BD Biosciences, San Jose, CA) at a ratio of 1:1. 100 μL of
this mixture containing 3 × 106 A375 cells was injected subcutaneously to the left-side
dorsal flank of each mouse. One week after the inoculation, the mice were randomized
into four groups (n = 7), and treatments started. UC-112 compound was suspended in
sterile PBS buffer and administered through intraperitoneally (i.p.) injection once per
day, 5 days per week, for 3 continuous weeks. Vehicle control group was i.p. injected
with the same volume (100 μL) of PBS buffer at the same dosing frequency. At the end
of the experiments, mice were euthanized, and tumor tissues were isolated and weighed
separately. Then one small piece (around 50 mg) from each tumor was cut and stored in
liquid nitrogen immediately. The rest of the tumor tissue was fixed in 10% buffered
formalin phosphate solution for more than 1 week before pathology staining analysis.
Tumor volume and body weight of each mouse were evaluated 3 times a week.
We calculated the tumor volume with the formula a × b2 × 0.5, where a and b represented
the larger and smaller tumor diameters. Data were presented as mean ± SD for each
group and plotted as a function of time. Tumor growth inhibition (TGI) ratio (%) was
calculated as 100 - 100 × [(T - T0)/(C - C0)], where T, T0, C, and C0 were the mean tumor
volume for the specific group on the last day of treatment, mean tumor volume of the
same group on the first day of treatment, mean tumor volume for the vehicle control
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group on the last day of treatment, and mean tumor volume for the vehicle control group
on the first day of treatment, respectively.
4.2.10 Pathology Analysis
Tumor tissues fixed in formalin buffer for more than 1 week were stained with
hematoxylin and eosin. All the slides were scanned to create a digital replica of the entire
tissue on a glass microscopic slide by using the ScanScopeXT at 0.25 pixel/μm.
4.2.11 TUNEL Assay
To evaluate the nuclear DNA fragmentation within the A375 tumor tissue,
Terminal deoxynucleotidyltranferase (TdT)-mediated dUTP nick end labeling (TUNEL)
assay was performed using the DeadEndTM Fluorometric TUNEL system (Promega,
Madison, WI) following the manufacturer's protocols. Briefly, the formalin-fixed and
paraffin-embedded tumor sections were deparaffinized and rehydrated before 100 μL of
20 μg/mL proteinase K solution was added to premeabilize the tumor sections. After preequilibration in room temperature for 10 minutes, tumor sections were incubated with
nucleotide mix and rTdT enzyme at 37°C for one hour. The reaction was stopped with
saline-sodium citrate (SSC) buffer and the tumor sections were washed with PBS to
remove the excess reagents. These slides were mounted in VECTASHIELD® + DAPI (H1500, Vector Labs, Burlingame, CA) to stain nuclei. Finally, coverslips were added and
the slides were analyzed immediately under a fluorescence microscope (EVOS® FL Cell
Imaging System, Thermo Fisher Scientific Inc., NY).
4.2.12 Statistical Analysis
Data were analyzed using Prism Software 5.0 (GraphPad Software, Inc., San
Diego, CA). The statistical significance (P value) was evaluated by one-way ANOVA
followed by nonparametric Dunnett’s test for in vitro apoptosis detection and in vivo
xenograft study. Every treated group was compared to the vehicle group separately.
4.3 Results and Discussion
4.3.1 Identification of Initial Hits from Virtual Screening
We started the study with shape-based virtual screening using the phase shape
program in Canvas. It initiates finding trial alignments based on the principle of the
distribution of atom triplets, then refines the top alignments to maximize the volume
overlap(260). The 3D structure of Smac N-terminus AVPI tetrapeptide (PDB ID: 1G73
(249)) in its bioactive conformation was selected as the query template to screen
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molecules within the prepared compound library that could achieve similar
conformations to that of the active AVPI peptide. In our study, the highest shapesimilarity score of UC library compounds reached 0.81; over 800 compounds had scores
over 0.75. Figure 4-1 illustrates the alignments generated from the similarity screening
where template ligand AVPI peptide overlapped well with representative hit compounds
UC-222 and UC-112.
To validate the theoretical interaction between the shape-based screening hits and
IAP protein, we docked the top 1000 hits into the Smac AVPI binding pocket in two
widely used crystal complexes of Smac-XIAP (X chromosome-linked IAP) BIR3 domain
(PDB ID:1G73 (249) and 1TW6 (258)) . We selected two widely used Smac-XIAP
complexes at this step because XIAP is the most characterized IAP and a direct inhibitor
of initiator caspase-9 (245, 261). Apoptotic resistance was found to correlate with
expression levels of XIAP in human prostate, melanoma, and non-small cell lung cancer
cells (247). In addition, the ability of XIAP to inhibit apoptosis has been shown to allow
melanoma cells to escape endoplasmic reticulum (ER) stress-mediated cell death (261).
Hit compounds with best docking scores in either of the crystal structures were examined
for their drug-like properties. Fifty hits from each of the two crystal structures (100 hits in
total and their binding poses on the AVPI pocket are shown in Figure 4-2) were selected
and combined to produce 71 unique final hits for subsequent in vitro assay against a
panel of cancer cells.
4.3.2 Validation of Virtual Screening Using In Vitro Anti-proliferation Assay
Here we selected four well-established cancer cell lines (two human melanoma
and two human prostate cancer) to first screen the hit compounds anti-proliferation
potency. Those cell lines had been used widely to evaluate the efficacy of IAP inhibitors
both in vitro and in vivo (254, 255, 262). We first performed a two-concentration quick
screening assay for the 71 unique hits identified in the previous step. Hits that displayed
more than a 10% growth inhibition at a concentration of 3 μM or 10 μM on either of
A375 or M14 melanoma cells after 48 h incubation are listed in the column diagram
(Figure 4-3). Compounds UC-274, UC-476, UC-112, and UC-222 (Table 4-1, upper
panel) achieved more than 50% growth inhibition in A375 or M14 cells at low micromolar concentration.
We subsequently determined the IC50 values for these four UC compounds and
embelin (a reference IAP inhibitor (246, 254) serving as a positive control) on an
expanded panel of human melanoma (A375 and M14) and prostate cancer (PC-3 and
DU145) cell lines (Table 4-1, lower panel). Embelin is a potent and non-peptidic small
molecular XIAP inhibitor with good in vivo antitumor and anti-inflammation activity.
Among the four, UC-112 was the most active compound: its IC50 was as low as 0.7 μM
against PC-3 cell line. All four UC compounds had comparable or better antiproliferation activity than did embelin (Table 4-1).
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Figure 4-1. In silico similarity alignments of template ligand, Smac N-terminus
tetrapeptide AVPI (blue stick), with representative UC compounds (UC-222 in
brown tube; UC-112 in yellow tube)
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Figure 4-2. In silico predicted binding poses of 50 hits selected for in vitro activity
evaluation docked into AVPI binding sides in different XIAP BIR3-Smac complexes
PDB IDs: A, 1G73; B, 1TW6; hits were displayed with grey thin sticks and AVPI was
presented with green tube stick.
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Figure 4-3. Cell growth inhibition percentages of XIAP inhibitor hits on human
melanoma A375 and M14 cells at 4 μM or 10 μM after 48 h incubation determined
by MTS assay (n =4)
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Table 4-1.
Growth inhibitory percentages of UC compounds at a concentration
of 3 μM or 10 μM (MTS assay, n = 4) and IC50 (μM) values of UC compounds in
comparison with embelin against cancer cell proliferation (SRB assay, n = 4)

Compound
ID
UC274

Growth
inhibition
of M14 cell
(%)
3
10
μM μM

IC50 (μM)

PC3

DU145

AVG
*

12.8 73.7 39.9 70.2 13.4 12.3 15.1
± 3.5 ± 2.4 ± 3.3 ± 1.1 ± 0.7 ± 0.4 ± 0.3

17.3 ±
2.9

14.5
± 1.1

UC476

16.7 84.0 20.6 85.3 10.4 10.2 12.8
± 2.3 ± 1.6 ± 2.0 ± 3.8 ± 0.2 ± 0.2 ± 2.1

11.4 ±
2.2

11.2
± 0.6

UC112

50.7 65.0 81.1 99.6 1.6 ± 2.5 ± 0.7 ±
± 5.1 ± 3.4 ± 1.7 ± 0.6
0.1
0.3
0.1

3.4 ±
0.8

2.1 ±
0.6

UC222

67.0 94.6 73.7 99.2 2.7 ± 3.5 ± 2.3 ±
± 1.6 ± 1.0 ± 2.0 ± 0.7
0.4
0.1
0.2

4.5 ±
1.7

3.3 ±
0.5

23.2 ±
3.7

17.8
± 2.5

Embelin

Structure

Growth
inhibition
of A375 cell
(%)
3
10
μM μM

ND

ND

ND

ND

A37
5

M14

14.3 20.7 13.0
± 3.2 ± 5.4 ± 1.8

ND: not determined. Data are shown as mean ± SEM. AVG*: average IC50 value was
calculated using the data across all four tested cell lines of the same compound.
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We also investigated the cell toxicity of these UC compounds on two noncancerous cell lines (Table 4-2). Compared with its average IC50 value in the tested
cancer cell lines, UC-112 has around 2.5 folds higher IC50 values on Hacat or HDFa cells.
The IC50 values of UC-222 have increased 8 to 12 folds in the tested non-cancerous cells,
compared with the average IC50 on the cancer cell lines.
4.3.3 Hit Compounds Increased Caspase Activities Significantly Better than
Embelin
The Smac N-terminus IAP binding motif interacts with the IAPs and protects
caspase function either directly or indirectly. Because the overexpression of IAPs in
cancer cells result in the suppression of caspase functions, the capability of raising
caspase activities is often used to measure the potency of IAP inhibitors (250-252).
Embelin was reported to increase caspase activity in PC-3 cells at a concentration of 40
μM after 42-h incubation (254). However, our pilot study showed that four most potent
UC compounds at the concentration of 40 μM would kill most of the cancer cells,
therefore making the measurement of caspase level below the assay detection limit. For
this reason, we used much lower concentrations for UC compounds and performed the
caspase functional Glo-assay (Figure 4-4A to D). All UC compounds effectively
increased the caspase-3/7 (the executor caspases) and caspase-9 (the initiator caspase)
levels on A375 and PC-3 cells in a time-dependent manner (Figure 4-4). In addition, UC222 at a concentration of 10 μM and UC-112 at a concentration of 4 μM (10 μM of UC112 was too high for this assay due to its higher potency) had significantly stronger (P <
0.01) caspase activation potency compared to embelin at 4 times or 10 times higher
concentration (40 μM).
4.3.4 Western Blotting Analyses of IAPs Level Change in Cancer Cells
Having established that the four UC hit compounds can potently increase the
caspase activities, we asked the question whether these compounds produced their effects
by directly inhibiting IAPs, since they were screened in silico as Smac N-terminus AVPI
mimetic molecules. To answer this question, we studied the changes of IAP levels in
cancer cells when they were treated by the two most potent UC compounds, UC-112 and
UC-222, or the reference IAP inhibitor embelin. While there were no significant changes
of XIAP, cIAP1, cIAP2, or survivin expression at short time incubation (3 h, data not
shown), when the incubation time was increased to 24 h, UC-112 at concentrations of 4
μM or 10 μM (Figure 4-5A) significantly suppressed survivin level on A375, PC-3, and
DU145 cell lines in a dose-dependent manner. UC-112 potently decreased survivin level
(94% and 97% at 4 μM and 10 μM, respectively) in A375 cells while its inhibition of the
other major IAPs (i.e., XIAP, cIAP1, cIAP2), which also interact with Smac, was much
weaker. At the same time point (24 h), UC-222 at concentrations of 4 μM or 10 μM
decreased the level of cIAP2 on PC-3 cells and XIAP on DU145 cells but only had very
mild effects on the survivin level in either cell line (Figure 4-5A).
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Table 4-2.
IC50 (μM) values of UC compounds in comparison with embelin
against normal cells proliferation (SRB assay, n = 4)
Cell line
type
Cancer
cell lines
Noncancerous
cell lines

Cell line
name
AVG*

UC-274

UC-476

UC-112

UC-222

Embelin

14.5 ± 1.1

11.2 ± 0.6

2.1 ± 0.6

3.3 ± 0.5

17.8 ± 2.5

Hacat

> 100

6.2 ± 1.8

5.6 ± 1.5

36.0 ± 2.3

43.6 ± 3.7

HDFa

42.8 ± 6.4

11.4 ± 2.5

5.2 ± 0.2

29.5 ± 7.1

3.1 ± 0.7

Data are shown as mean ± SEM. AVG*: average IC50 value on four cancer cell lines
(A375, M14, PC-3, DU145).
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Figure 4-4. Relative in vitro caspase activity of human melanoma A375 or human
prostate cancer PC-3 cells after treatment with UC compounds or embelin at
different concentrations (n = 4)
Testing concentrations (4 μM or 10 μM) of UC compounds were selected in reference to
their in vitro anti-proliferation potency. All the relative light unit (RLU) data were
normalized according to the cell viability results read from the same well in a 96-well
plate. A, caspase-3/7 in A375 cells. B, caspase-3/7 in PC-3 cells. C, caspase-9 in A375
cells (48 hr incubation). D, caspase-9 in PC-3 cells (48 hr incubation). **P < 0.01
compared to corresponding results of embelin group.
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Figure 4-5. Compounds UC-112 and UC-222 down-regulate the IAP levels in vitro
A, Western blotting analysis using cell lysates of A375, PC-3, or DU145 cells that have
been treated by compounds at concentrations of 4 or 10 μM for 24 h. B, at concentration
of 40 μM, Western blotting analysis showed that UC-112 and UC-222 can effectively
induce degradation of XIAP and survivin, after 8-h or 24-h incubation. C, Silencing
survivin or XIAP gene in A375 or PC-3 cells increased the IC50 values of UC-112.
Treatment started at 24 hr after the siRNA transfection. The cell viability after 48 hr
treatment was determined using MTS assay (n = 4). D, comparison between compound
UC-112 and YM155 regarding the potency of reduced survivin level in A375 or PC-3
cells. Photographs show representative data from three independent experiments. E, MTS
assay (n = 4) revealed that UC-112 overcomes Pgp-mediated multidrug resistance much
better than does YM155.
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In comparison, the inhibition effects of embelin at low concentrations (4 μM
and10 μM) on the IAP levels were not clear in these cell lines (Figure 4-5A). When we
increased its concentration to 40 μM, embelin could inhibit XIAP expression in PC-3
cells with an 8-h incubation (Figure 4-5B), consistent with literature report (254). In
contrast, UC-112 at 40 μM only moderately decreased the level of XIAP but substantially
down-regulated level of survivin in A375 cells (Figure 4-5B). UC-222 at this
concentration (40 μM) was most potent in decreasing XIAP levels in A375 and DU145
cells but PC-3 cells were more resistant to the UC-222 treatment. Thus, UC-112
demonstrated selective inhibition against survivin among the IAPs tested (Figure 4-6).
To validate whether the toxicity of UC-112 on cancer cells results from its downregulation effects on IAP levels, we silenced the gene of survivin or XIAP by transfecting
A375 and PC-3 cells with specific siRNAs. Then the anti-proliferation efficacy of UC112 on these transfected cancer cells was determined with MTS assay and the data was
shown in Figure 4-7. Compared to the results from the non-transfected (blank group) or
non-specific siRNA transfected cells, IC50 values of UC-112 increased 7 to 10 folds when
either XIAP or survivin expression was silenced.
Survivin is a unique and smallest member of inhibitor of apoptosis proteins
(IAPs). It is highly expressed in most types of cancer but has very low or undetectable
expression in differentiated normal tissues (161, 194, 263-266). Consistent with this
differential expression, survivin inhibitors have been shown to have broad efficacy in
many types of cancer and low toxicity (157, 166). Additionally, survivin expression has
been well correlated with tumor progression, resistance to existing therapies, and poor
patient survival (231, 263, 267, 268). Survivin is involved in a myriad of oncogenic
pathways and is considered to be a nodal protein. Recent studies have also revealed that
high levels of survivin positively correlate with the over-activation of known oncogenic
pathways (HIF-1α (157, 231), HSP90 (158, 159), PI3K/AKT (160, 161), ERK (162), Bcl-2
(269, 270) and RAS pathways (163, 164)) but negatively correlate with tumor suppressor
genes (p53, PTEN (165-167)). Together, these characteristics make selective inhibition of
survivin an ideal target for novel cancer drug discovery.
Encouraged by the results that compound UC-112 is a relatively potent inhibitor
of survivin, we quantified the potency of the compound by incubating A375 and PC-3
cells with serially diluted UC-112 solutions (from 4 μM to 10 nM). We also selected
YM155 (204, 206, 207, 262), a highly efficient survivin promoter inhibitor as the
experiment’s positive control. Results (Figure 4-5D, Figure 4-6B) showed that UC-112
significantly down-regulated survivin levels (> 50% compared to control group) on A375
cells at a concentration of 400 nM in 24 h, while a higher concentration (1 μM) or longer
treatment time (48 h) (data not shown) was needed in PC-3 cells. YM155 showed to be a
more potent survivin inhibitor and strongly inhibited the expression of survivin at
concentration as low as 40 nM in A375 cells or 100 nM in PC-3 cells, consistent with
data in published reports(204, 207). No significant change in XIAP levels was observed
in either cell line treated with either UC-112 or YM155 at any concentrations tested. This
observation confirmed that compound UC-112 could selectively decrease the survivin
protein level over the levels of other IAP family proteins including the XIAP. Although
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Figure 4-6. Lane density quantification data of western blotting analysis results
(A375 cells) in (A) Figure 4-5A and (B) Figure 4-5C
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Figure 4-7. IC50 values of UC-112 increased in survivin or XIAP gene silenced
A375 and PC-3 cells
A, western blotting showed that siRNA transfection specifically silenced the expression
of survivin or XIAP in A375 and PC-3 cells. B, IC50 values of UC-112 tested on different
siRNA transfected cells in MTS assay (n = 4).

69

YM155 is extremely potent in binding and inhibiting the survivin promoter, its main
drawback is that it is a substrate for the Pgp drug efflux pump (271). In fact, when tested
in Pgp overexpressed M14/MDR1 melanoma cells, UC-112 have comparable IC50 values
in the resistant M14/MDR1 and the sensitive M14 parental cells (Figure 4-5E and Table
4-3, small resistance index is desirable to overcome drug resistance), displaying a small
resistance index value around 2. In contrast, the resistance index of YM155 was larger
than 2900, consistent with the finding that it is a Pgp substrate.
4.3.5 Proteasome Inhibitor MG132 Rescued the Down-regulated Survivin Levels in
Cancer Cells Treated by UC-112
Although the degradation mechanisms of survivin still need to be clearly
delineated, XIAP-associated factor 1 (XAF1) was reported to activate E3 activity in
XIAP and directly led to survivin degradation through ubiquitination (172). To further
understand the possible mechanism leading to survivin down-regulation by UC-112, we
hypothesized that this compound involved the ubiquitin-related degradation process of
survivin. To test this hypothesis, we determined whether the addition of a panproteasome inhibitor, MG132, would counteract the ubiquitin-mediated degradation
process and rescue survivin from the action of UC-112. As shown in Figure 4-8A, coincubation of pan-proteasome inhibitor MG132 (10 μM) with UC-112 for 24 h
effectively rescued the survivin levels in PC-3 and DU145 cells. MG132 at 10 μM in this
study was unable to rescue survivin in A375 cells because these cells are more sensitive
to the survivin down-regulation effect resulted from UC-112 treatment. However, if
A375 cells were pretreated with higher concentrations of MG132 (20 μM or 50 μM) for 6
h followed by incubation with UC-112 for another 24 h after washing away MG132, the
survivin level could be rescued from UC-112 treatment (Figure 4-8B). The results
suggest that UC-112 may produce its survivin inhibition effect, at least in part, via the
ubiquitin-mediated degradation of survivin.
4.3.6 UC-112 Arrested A375 Melanoma Cells in G1 Phase
It is well established that survivin plays complex and critical roles during cell
mitosis as a chromosomal passenger protein to promote chromosome segregation and
cytokinesis in the G2/M phase of the cell cycle (194, 264, 267). Survivin as a cytoplasmic
protein is dominantly expressed in the G2/M phase, followed by a rapid degradation via
the ubiquitin-proteasome pathway during G1 (161, 170, 264, 267). Therefore, the survival
of cancer cells in the G2/M phase is highly dependent on the presence of survivin, while
cells in the G1 phase are insensitive to survivin expressions. If UC-112 potently degrades
survivin in cancer cells, then we would expect that cells in the G2/M phase will collapse
while the less survivin-dependent cells in the G1 phase will remain, leading to an overall
G1 phase accumulation upon UC-112 treatment. To test this hypothesis, we performed
cell cycle analysis to determine how UC-112 would influence the cell cycle distribution.
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Table 4-3.
UC-112 overcomes Pgp-mediated drug resistance much better than
YM155 (n = 4)
IC50
Compound ID

M14 (nM)

M14/MDR1 (nM)

Resistant Index

UC-112

780 ± 32

1798 ± 140

2.3

YM155

3.4 ± 0.5

>10,000

>2,941

Colchicine

5.0 ± 0.5

345 ± 12

69

Resistant Index was calculated by dividing the IC50 in resistant cells by the IC50 in the
sensitive parental cells. Higher RI values suggests stronger drug resistance
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Figure 4-8. Proteasome inhibitor MG132 can rescue survivin inhibition by UC112
A, Western blotting analysis after co-incubation of MG132 (10 μM) with UC-112 for 24
h in A375, PC-3, and DU145 cells. B, A375 cells were pretreated by high doses of
MG132 (20 μM or 50 μM) for 6 h and washed once by blank cell culture medium. Then
UC-112 was added for following 24 h incubation. Photographs showed representative
data from three independent experiments. C, cell cycle analysis of A375 cells incubated
with 1 μM or 4 μM UC-112 for 24 h (n = 3).
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The results (Figure 4-8C) of flow cytometry analysis showed that incubation with
1 μM UC-112 for 24 h caused A375 cells to accumulate in the S phase, with a concurrent
reduction of cells in the G2/M phase. When the concentration of UC-112 increased to 4
μM, a large percentage of A375 cells (76 ± 2% in treatment vs. 51 ± 1% in vehicle
control) accumulated in the G0/G1 phase with escalated sub-G1 events, which indicated
induction of cell apoptosis. The percentage of cells remaining in the G2/M phase was
decreased (13 ± 1% in treatment vs. 21 ± 2% in vehicle control). In this study, UC-112
blocked the A375 cell cycle in G1 phase in a dose-dependent manner. This observation is
consistent with the proposed mechanisms of action for UC-112 as described above,
providing additional evidence that UC-112 targets survivin degradation, a posttranslational modification process. In contrast, down-regulation of survivin gene
expression by YM155 was a cell cycle-independent event without G1 cell arrest in a wide
panel of cancer cells (272). Thus, unlike YM155, UC-112 down-regulated the survivin
levels in cancer cells more likely by promoting the ubiquitin-mediated degradation of
survivin rather than by altering the expression of survivin at the transcription level.
4.3.7 UC-112 Inhibited Tumor Growth in a Melanoma Xenograft Model In Vivo
To further investigate the therapeutic potential of compound UC-112, we
evaluated its anti-tumor efficacy in an A375 xenograft mouse model. We first estimated
the maximum tolerable dose (MTD) in mice. UC-112 was well tolerated in mice up to
200 mg/kg which was the highest dose we tested. The very low toxicity displayed by UC112 is consistent with the above evidence suggesting that UC-112 is a selective survivin
inhibitor, because survivin is highly expressed in tumor cells but minimally expressed in
normal tissues (157, 263, 266). Considering realistic doses that are normally used
clinically, we decreased the dose of UC-112 to 10% (20 mg/kg) and 20% (40 mg/kg) in
subsequent in vivo efficacy studies. After 3 weeks of continuous treatment, UC-112 was
highly effective in inhibiting melanoma tumor growth in the A375 xenograft model in a
dose-dependent pattern (Figure 4-9A and Figure 4-10) without causing (>10%) body
weight loss in nude mice (Figure 4-9B). Treatment with UC-112 at 20 mg/kg achieved
65.59 ± 19.56% tumor growth inhibition (TGI) compared to vehicle control group, while
the dose at 40 mg/kg almost completely inhibited tumor growth (TGI was 95.23 ±
3.11%). The average tumor weight in the UC-112 40-mg/kg treatment group was only
13.56% of that in the vehicle control group (Figure 4-9C). To determine whether the
potential mechanisms of action for UC-112 observed in vitro will remain in vivo, we
compared the IAP protein expressions between the control and treatment tumors. As
shown in Figure 4-9D, UC-112 significantly reduced both survivin and XIAP levels in
the lysates of fresh tumors isolated at the end of the treatment, confirming the in vivo
efficacy of UC-112 was at least in part through the strong inhibition of IAPs.
Hematoxylin and eosin staining showed that UC-112 induced extensive tumor cell death
in these A375 melanoma tumors (Figure 4-9E). Furthermore, TUNEL assay which
measured nuclear DNA fragmentation (Figure 4-9F) clearly showed the dose-dependent
increasing of apoptosis in tumor sections of UC-112 treatment groups. All these results
are consistent with our in vitro observations that UC-112 could efficiently inhibit tumor
cell proliferation by down-regulating the level of IAPs, especially survivin protein.
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Figure 4-9. UC-112 (20 mg/kg and 40 mg/kg) strongly suppress melanoma tumor
growth in an A375 xenograft mouse model (n = 7, i.p. injection 5 days per week)
A, tumor volume growth curve. B, mice body weight versus time plot. C, tumor weight
comparison bar graph. **P < 0.01, ***P < 0.001 compared to the corresponded results of
vehicle group. D, Western blotting analysis of survivin and XIAP levels in fresh tumor
lysates. Each lane represents tumor tissue lysate from a single mouse. E, representative
immunohistochemistry images for H&E staining of A375 tumor tissue sections. The scale
bar (yellow) in each image represents 200 μm. Photographs show representative data
from three independent experiments. F, representative fluorescence microscope images
for TUNEL assay of A375 tumor tissue sections. The scale bar (white) in each image
represents 100 μm.
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Figure 4-10. Tumor images of in vivo anti-tumor efficacy evaluation of UC-112 (20
mg/kg and 40 mg/kg) on A375 xenograft nude mice model (n = 7, i.p. injection five
days per week for three continuous weeks)
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CHAPTER 5. ANTI-CANCER EFFICACY, PHYSIO-CHEMICAL PROPERTY
AND TARGET VALIDATION STUDIES OF OPTIMIZED UC-112 ANALOGS*
5.1 Introduction
We recently discovered that UC-112, [5-((benzyloxy)methyl)-7-(pyrrolidin-1ylmethyl)quinolin-8-ol], is a potent, selective survivin inhibitor (273). UC-112 inhibits
tumor cell growth in several cancer cell lines in vitro and suppresses melanoma tumor
growth in vivo (273). Mechanistic studies indicated that UC-112 selectively inhibits
survivin expression and induces strong cancer cell apoptosis. By performing targeted
structural modifications, a series of novel UC-112 analogs were obtained. Biological
evaluation of these new analogs revealed their excellent anti-proliferative activity against
several cancer cell lines including multidrug-resistant phenotypes. Mechanism of action
studies confirmed that these new UC-112 analogs maintained their mechanisms of
actions by selectively down-regulating the level of survivin among other IAP family
proteins. Preliminary in vivo evaluation for the most active compound MX106
demonstrated its efficacy against human melanoma tumor growth.
5.2 Materials and Methods
5.2.1 Cell Culture and Cell Viability Assay
The anti-proliferative effect of UC-112 and its analogs were tested in human
melanoma (A375, M14 and M14/LCC6MDR1) and human prostate cancer (PC-3) cell
lines. All the cell lines were purchased from ATCC (American Type Culture Collection,
Manassas, VA). The cancer cells were cultured using the supplemented cell culture
medium as described before (259) at 37oC in a humidified atmosphere containing 5%
CO2. 5000 cells in logarithm growing phase were seeded overnight into each well of a
96-well plate. Then the cells were continuously incubated with sequential diluted
compound solution (10 nM to 100 μM, 100 μl per well) in cell culture medium. After 48
h treatment, the cell viability was determined in MTS assay and IC50 was calculated (n =
4) as described before (127, 273).
5.2.2 NCI-60 Screening
Four compounds including the parental compound UC-112 were submitted to
National Cancer Institute for its NCI-60 cell line screening, initially tested at one
* Modified with permission. Xiao M, Wang J, Lin Z, Lu Y, Li Z, White S, Miller D, Li
W. Design, synthesis and structure-activity relationship studies of novel survivin
inhibitors with potent anti-proliferative properties. PLOS ONE. DOI:
10.1371/journal.pone.0129807
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concentration (10 μM), and subsequently selected for full five concentration testing
following the standard protocols disclosed by NCI (274). In brief, cells were plated into
96 well micro-titer plates 24 h prior to the treatment of compound solution for 48 h, then
the cell viability was read out through absorbance of sulforhodamine B (SRB) staining.
5.2.3 Western Blotting
Lysates of A375 cells treated by the compound solution for 24 h were used to
determine the change of IAP protein levels through western blotting. Primary rabbit
antibodies against survivin, XIAP, cIAP1, cIAP2, livin, p53 and GAPDH were purchased
from Cell Signaling Technology, Inc. (Danvers, MA) and used according to manufacture
instructions as reported previously (273). Protein lane intensities were quantified by
ImageJ software (US National Institutes of Health, Bethesda, MD).
5.2.4 DARTS Assay
Drug affinity responsive target stability (DARTS) assay was performed to identify
the protein targets of UC-112 analogs in A375 or M14 cell lysates following the
protocols described in Dr. Jing Huang’s publications (275, 276). In brief, A375 or M14
lysates were prepared in nondenaturing M-PER lysis buffer (Thermo Fisher Scientific,
Waltham, MA) with protease and phosphatase inhibitors. Then TNC (Tris, NaCl, CaCl2)
buffer was added into cell lysates before the total protein concentration of lysate being
determined by BCA protein assay kit (Thermo Fisher Scientific, Waltham, MA). Next the
lysates were split into two groups: one group was added with compound of interest
solution, the other group was added with same amount of vehicle (DMSO). The samples
were mixed thoroughly and incubated at room temperature for 1 h. Then 10 mg/mL
pronase stock solution was added into both compound treated or vehicle control groups to
achieve the final dilution of 1:100, 1:300, 1:1000 and 1:3000. One aliquot of each group
was kept as un-digested control. The proteolysis was performed at room temperature for
30 min before ice cold protease inhibitor stock being added into the mixture. Then SDS
loading buffer was added into all the samples and heated to 70 qC for 10 min. Finally, the
results were analyzed by SDS-PAGE and immunoblotting.
5.2.5 Molecular Modeling
The molecular docking studies were performed following similar procedure as
described before (273, 277) in Schrodinger Molecular Modeling Suite 2014 (Schrodinger
Inc., Portland, OR). All the ligands were prepared to generate various conformation
before being docked into the Smac AVPI binding site of a human survivin crystal
structure (Protein Data Bank entry: 3UIH). Molecular dynamic calculation was done after
the docking to minimize the energy of potential ligand binding poses. Results were
visualized using the Maestro interface of the Schrodinger software.
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5.2.6 Liver Microsomal Stability Study
Liver microsomal metabolic stability was conducted by incubating the
compounds of interest (0.5 μM) in a total reaction volume of 1 mL containing 1 mg/mL
microsomal in reaction buffer [0.2 M of phosphate buffer solution (pH 7.4), 1.3 mM
nicotinamide adenine dinucleotide phosphate (NADP+), 3.3 mM glucose-6-phosphate,
and 0.4 U/mL glucose-6-phosphate dehydrogenase] shaking at 37°C 100 rpm. The
NADPH regenerating system (solution A and B) was obtained from BD Biosciences
(Bedford, MA). Aliquots (100 μL) from the reaction mixtures were sampled at 0, 5, 10,
20, 30, 60, 90 and 120 min. Ice cold acetonitrile (150 μL) containing 200 nM of the
internal standard was added to quench the reaction and to precipitate the proteins.
Samples operated under similar condition using heat-denatured microsomal were used as
controls. After centrifugation at 13,000g for 15 min, the supernatant was submitted for
LC-MS/MS analysis.
5.2.7 Plasma Protein Bounding Study
Plasma (human and rat) protein binding was analyzed using a rapid equilibrium
dialysis (RED) device (Thermo Fisher Scientific, Waltham, MA) containing dialysis
membrane with molecular weight cut-off at 8,000 Daltons. 50 μM test compound was
sparkled into the plasma chamber. Then dialysis was performed at 37 °C with 100 rpm
shaking for 4 h as per manufacturer’s recommendation. At the end of dialysis, 50 μL
aliquot from both plasma chamber and buffer saline chamber was removed and quenched
with equal volume of ice cold acetonitrile with internal standard in -20 °C for 20 min.
After centrifugation at 13,000g for 15 min, the supernatant was submitted for LC-MS/MS
analysis. Free drug percentage was calculated as peak area of test compound in dialysate
buffer divided by peak area of test compound in dialysate plasma.
5.2.8 In Vivo Anti-tumor Efficacy Test
3 × 106 A375 cells were implanted into the left-side dorsal flank of each nude
mouse (n = 5) to establish the human melanoma A375 tumor xenograft model as
described previously (129, 273). Compound MX106 were first dissolved in DMSO then
diluted by 2% methylcellulose PBS buffer. The proportion of DMSO in final solution
was kept at lower than 5%. Mice body weight and the size of tumor were closely
monitored during the 3 week continuous treatment (i.p. injection, one dose per day five
days per week). At the end point of the treatment, mice were sacrificed after anesthesia.
5.2.9 TUNEL Assay
A375 tumor tissues collected from the in vivo efficacy study in the above were
fixed in formalin phosphate buffer for one week. Then the tissues were processed to get
paraffin embedded sections. TUNEL assay was performed using DeadEndTM

78

Fluorometric kit (Promega Corporation, Madison, WI) following manufacturer’s
instructions. By the end of the experiment, VECTASHIELD® Hard SetTM mounting
medium with DAPI (Vector Lab, Inc., Burlingame, CA) was used to mount the tumor
slides and stain the nuclei. The final slides were analyzed immediately under a
fluorescence microscope (EVOS® FL Cell Imaging System, Thermo Fisher Scientific
Inc., NY).
5.3 Results and Discussion
5.3.1 UC-112 Analogs Could Overcome Multidrug Resistance
The co-existing of survivin and drug resistant marker in tumor tissue has hindered
the in vivo anti-cancer activity of survivin inhibitors. In order to determine whether the
new analogs we made can overcome multidrug resistance (MDR), we compared the
activity of those analogs against multidrug-resistant melanoma cells (M14/LCCMDR1)
and their parental sensitive cancer cells (M14). This pair of cell line is well validated and
widely used to assess whether the drugs can overcome Pgp-mediated MDR (278-280).
Our three best compounds MX86, MX35 and MX106 together with the most successful
small molecule survivin inhibitor YM155 were tested on both the MDR melanoma cells
and their parental cells (Table 5-1). The resistance index is calculated by dividing the
IC50 value of the resistant cell line by IC50 value of the sensitive parental cell line. So the
smaller this value, the better resistance overcoming effect obtained. As this table shows,
compounds MX86, MX35 and MX106 all have very small resistance indexes (1.8, 1.9
and 2.3 respectively). Their activity in the resistant cell line is comparable with that in the
parental cell line. For existing survivin inhibitor, YM155, although it is very potent in
parental cell line (IC50 at 3 nM), its activity in resistant cell line is considerably lower
(IC50 is higher than 10 μΜ, resistance index is higher than 2941). This data indicate that
the new UC-112 analogs can circumvent Pgp-mediated multi-drug resistance and are
distinct from that of YM-155.
5.3.2 UC-112 Analogs Showed Good Anti-proliferation Effects with Selectivity in
NCI-60 Cell Line Screening
UC-112 and three potent analogs MX86, MX106 and MX35 were submitted to
NCI for its one-concentration (10 μM) screening against the NCI-60 cell lines. All four
compounds showed good activity and were selected for the subsequent five doses testing
to determine their growth inhibition potency (GI50) in the NCI-60 cell lines. As shown in
Figure 5-1, structure modification from UC-112 to our best compound MX106 has
improved the average GI50 by nearly four times (2.2 μM for UC-112 vs. 0.5 μM for
MX106).
The heat map in Figure 5-2 summarizes the compound growth inhibition pattern
which is characterized by the GI50 mean values from NCI-60 screening. UC-112 and its
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Table 5-1.
In vitro anti-proliferation activities of UC-112 analogs determined by
MTS assay (n = 4)
IC50 ± SEM(μM)
Structure

ID

X R1

A375

PC-3

M14

UC-112

O H

MX35

S H

MX86

O Br

MX106

O iPr

1.9 ±
0.6
1.4 ±
0.3
0.9 ±
0.2
0.9 ±
0.1
0.003
±
0.002

1.6 ±
1.0
1.1 ±
0.1
0.7 ±
0.3
0.7 ±
0.1
0.005
±
0.002

2.1 ±
0.3
1.4 ±
0.2
1.0 ±
0.2
0.8 ±
0.2
0.003
±
0.001

YM155

M14/LCC
6MDR1
3.2 ± 0.5

Resistance
Index
1.5

2.9 ± 0.6

2.1

1.8 ± 0.6

1.8

1.8 ± 0.4

2.3

> 10

> 2941

Resistance Index was calculated through dividing IC50 value in resistant cell line
(M14/LCC6MDR1) by IC50 in sensitive cell line (M14) for each compound.
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NCI-60 Average GI50/ μM

3.5

3
2.5
2
1.5
1
0.5
0

UC-112 MX35 MX86 MX106
Figure 5-1. Average GI50 data for UC-112, compound MX35, MX86 and MX106
tested in NCI-60 anti-proliferative screening
Data is shown with mean ± SD as bar graph.
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new analogs showed interesting selective growth inhibition behavior within the NCI 60
cell lines. The GI50 value of compound MX106 in renal cancer cell line UO-31 was as
low as 52.5 nM. Interestingly, two other cell lines, HCT-15 (colon cancer) and
NCI/ADR-RES (ovarian cancer), were also particularly sensitive to the treatment of
UC-112 and its analogs, with lowest GI50 value (highest activity) for compound MX106
at 46.8 nM and 50.1 nM, respectively. Since colorectal adenocarcinoma HCT-15 cells
intrinsically expresses moderate levels of Pgp, multidrug-resistance-associated protein
(MRP) and lung-resistance-associated protein (LRP) (281), and ovarian cancer
NCI/ADR-RES cells are naturally over-expressing MDR1 and resistant to various
chemotherapies including doxorubicin (282), these data have supported our findings that
UC-112 and its analogs could effectively overcome the multidrug resistance in vitro.
5.3.3 Mechanism of Action Studies
In our recently report (273), UC-112 exerted its tumor killing effect by selectively
inhibiting the expression of survivin. In order to determine whether the new UC-112
analogs maintained the same mechanism of action, we performed the western blotting
assay for MX106 in A375 and PC-3 cells (Figure 5-3A). Compound MX106 dosedependently suppressed survivin level in these two cancer cell lines, while the levels of
other IAPs were minimally affected. The presence of compound MX106 at 300 nM for
24 h reduced survivin levels over 50% in both A375 and PC-3 cells (lane density was
quantified by ImageJ software, data not shown). Interestingly, A375 is a p53 wild type
cancer cell, whereas PC-3 is a p53 null cancer cell. As shown in Figure 5-3B, UC-112
and MX106 reduced the level of survivin in both A375 and PC-3 cells, which indicated
the survivin down-regulation effects of UC-112 and MX106 is not p53 status dependent.
Next, we have conducted DARTS assay which is designed on the fact that the
protease susceptibility of the target protein will decrease upon ligand binding. DARTS
methodology is developed for general identifying protein-ligand interactions and has
been proved to be universally applicable without acquiring the modification of ligand or
targeted protein (275, 276). A375 and M14 cell lysates were pre-incubated with 1 μM
MX106 before proteolysis with pronase at gradient concentrations. Immunoblotting
results in Figure 5-4 revealed that incubation with MX106 protected the survivin protein
from the digestion of pronase, comparing with untreated samples. Non-target proteins
like GAPDH were non-differentiated digested by pronase with or without the presence of
MX106. Furthermore, pronase digestion of XIAP, cIAP1 and cIAP2 proteins was not
protected by the pre-incubation of MX106 in our study. The observation indicated the
existing of some specific interaction between MX106 and survivin protein, which made
the later more resistant to pronase digestion in A375 and M14 cell lysates.
5.3.4 Molecular Modeling Study
To understand the observed improvement in potency of compound MX106 over
its parental compound UC-112, we developed a molecular model and performed the
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Figure 5-2. Heat map showing the GI50 values (nM) for UC-112 and three analogs
in the NCI-60 screening
High intensity (blue) cells indicate high activity and low intensity (red) cells indicate low
activity. Average GI50 values were calculated for each compound, separately.
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Figure 5-3. Western blotting analysis of MX106 in A375 and PC-3 cell lines
A, representative images of western blotting analysis of A375 or PC-3 cells treated with
gradient increasing concentrations of MX106 for 24 h. B, representative images of
western blotting analysis of A375 or PC-3 cells treated with 1 μM UC-112 or MX106 for
2 h or 20 h.
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Figure 5-4. Representative DARTS results for pronase-digested A375 or M14 cell
lysates
Immunoblotting showed protection of the target protein, survivin, by the incubation with
MX106, whereas digestion of the non-target proteins like GAPDH was unchanged.
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molecular docking study using the complex of human survivin-Smac AVPI (PDB entry:
3UIH). As shown in Figure 5-5A, UC-112 displayed several interesting interactions with
the survivin protein BIR domain: (1) two hydrogen bonding interactions between the
A/B-ring of UC-112 and residue Asp71; (2) one hydrogen bonding interaction between
the D-ring nitrogen and residue Glu68; and (3) an π- π stacking interaction between the
A/B-ring of UC-112 and residue Typ67 (Figure 5-5A). Examination of this proposed
binding pose clearly suggests that the un-substituted phenyl ring of UC-112 failed to
occupy a hydrophobic groove (cycled with green dash line in Figure 5-5A), and a
properly sized, non-polar para-substitution (e.g., an isopropyl moiety as in compound
MX106) to this ring would fill this groove and also provide excellent overlap with the
bioactive AVPI peptide (Figure 5-5B). The binding mode is consistent with our
experimental results. Further refinement to this model, and ultimately an X-ray crystal
structure will greatly facilitate the future optimization of this scaffold.
5.3.5 In Vivo Anti-tumor Efficacy Assessment
Since our in vitro study showed that compound MX106 has the highest antiproliferative potency in this series of UC-112 analogs, we selected MX106 to test its in
vivo efficacy against tumor growth in a human melanoma A375 xenograft model through
i.p injection. As shown in the Figure 5-6A and B, compound MX106 inhibited the
growth of A375 xenograft tumor in a dose-dependent manner during the three weeks of
continuous treatment group is 53% and 79% slower than the vehicle control group,
respectively. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
assay, which measured the nuclear DNA fragmentation, showed that a high dose (40
mg/kg) of compound MX106 treatment caused the widely-spread cell apoptosis inside
the tumor tissues (Figure 5-6C).
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Figure 5-5. Potential binding pose of UC-112 and compound MX106 in the Smac
N-terminus tetra-peptide AVPI binding site of survivin crystal structure (PDB
entry: 3UIH) .
The surface of AVPI binding site in survivin was colored according to residue charge
(blue for positive while red for negative). A, UC-112 (green tube) formed hydrogen
bonds with residue Asp71 and Glu68 on the survivin protein BIR domain. B, compound
MX106 (orange tube) displayed similar binding pose with UC-112 but had better
occupied the grove toward the N-terminus of survivin protein. And this pose was
overlapping well with the binding mode of native ligand, Smac AVPI (green stick).
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Figure 5-6. In vivo anti-tumor efficacy of compound MX106
A and B, MX106 effectively inhibited the growth of A375 xenograft tumor after three
weeks continuous treatment (i.p. injection) in a dose-dependent manner (A) without
causing obvious decrease of mice body weight (B). C, Representative images of TUNEL
assay using the formalin-fixed tumor sections.
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CHAPTER 6.

SUMMARY AND FUTURE DIRECTION

In the combination project, since one of the major hallmarks for tubulin inhibitors
is their ability to strongly arrest cells in the G2/M phase, we hypothesized the
combination of vemurafenib and a tubulin inhibitor would synergistically arrest
melanoma cells, leading to enhanced apoptosis, and overcome acquired resistance. In this
study we selected novel tubulin inhibitors, ABI-231 and ABI-274, to investigate its
combination with vemurafenib against melanoma tumors. We developed vemurafenibresistant human melanoma cell line A375RF21 and MDA-MB-435 VemR. Results
showed that the combination of ABI compound and vemurafenib had strong synergy in
vitro. We confirmed that the synergy is unlikely through enhanced inhibition of tubulin
polymerization or diminished of p-ERK activation. Instead, our experimental results
revealed that this combined treatment overcomes the acquired vemurafenib-resistance
through enhanced apoptosis induction produced by synergistic G1 and G2/M cell-cycle
arrest and substantially impaired the survival signaling pathway related to AKT
phosphorylation. We showed that the strong synergy observed in vitro clearly translated
to significant efficacy in vivo when tested in a vemurafenib-resistant xenograft model.
Further immunohistochemistry analyses on tissue sections confirmed the strong
inhibition of tumor proliferation and the diminished activity of pAKT. The in vivo studies
presented here show an effective combination treatment in tumor cells that are already
vemurafenib-resistant by using A375RF21 xenograft models. It is conceivable that if we
used the combination before tumor cells became resistant to vemurafenib, tumor
regression may be more enhanced and we could significantly delay or even prevent the
development of resistant tumor cells. This could translate into at least a substantially
longer progression-free time in patients, and/or enhanced disease regression. Collectively,
our study offers the first direct evidence and a rationale for combining a potent tubulin
inhibitor with an inhibitor targeting the RAF/MEK/ERK pathway for greatly improved
therapy for melanoma patients. To further conduct this project, we need to address three
types of questions: 1) can we find a better methodology other than CI values to precisely
evaluate the combination effect test in vitro; 2) can we establish more BRAF inhibition
resistant models with known and clinical relevant mechanisms; 3) can we deal with the
tumor heterogeneity, which is extremely important in control of acquired resistance to
small molecule cancer therapy, through rational designed combination treatment.
In the survivin inhibitor project, using shape-based virtual screening combined
with biological activity evaluation, we identified four Smac mimetic hits with higher or
comparable anti-proliferation potency compared with embelin. The overall hypothesis is,
theses hit compounds can mimic the function of Smac, which is the endogenous inhibitor
of IAPs including survivin, and thus trigger the programmed apoptosis in cancer cells.
The four identified hits significantly activated caspase-3/7 and caspase-9 function in
human melanoma A375 and prostate cancer PC-3 cell lines. Compounds UC-112 and
UC-222 strongly suppressed XIAP and survivin levels in vitro and had scaffolds
amicable for modification to further improve their potency. In particular, compound UC112 showed good selectivity in decreasing the level of survivin (BIRC5) in a dosedependent manner, possibly through the ubiquitin-mediated degradation pathways, and it
also has the potential to overcome Pgp-mediated multidrug-resistance which is a
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limitation for many of the existing IAP inhibitors. More excitingly, UC-112 displayed
very low toxicity, showed potent efficacy of tumor growth inhibition in an A375
melanoma xenograft model, and maintained its mechanisms of actions in vivo. This
integrated chemical biology study provided promising lead compounds amicable for
further structural optimization in order to develop new selective IAP inhibitors as
potential therapeutic agents for resistant cancers, either as a single agent or in
combinations with existing drugs. Novel analogs which are structurally modified from
the lead compound UC-112 have showed excellent anti-proliferative activities and could
also effectively overcome Pgp-mediated multiple drug resistance. The most potent
compound MX106 has selectively down-regulated the level of survivin as the parent
compound UC-112 in a p53 status independent manner. And compound MX106 greatly
inhibited the growth of A375 xenograft tumor in vivo. These findings are encouraging but
target validation work is essential to further direct the future study of this project. In other
words, we need to know why the level of survivin protein is decreased after the treatment
of UC-112 and its analogs. Considering the regulation mechanisms of survivin, we
should investigate whether the compounds are promoting degradation or inhibiting the
expression of survivin. Meanwhile, the off-target effect of this series of compounds need
to be properly evaluate although in the xenograft models, i.p. injection for three
continued weeks at doses up to 40 mg/kg did not significantly affect the nude mice body
weight.
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